nct_id,ctgov_group_code,arm_name_bas,same_name_as_drug_compare,name_drug_compare,classification,category,title,description,units,param_type,param_value,dispersion_type,dispersion_value
NCT00149227,B1,Valsartan,TRUE,Valsartan,,,Age,,years,Mean,65.8,Standard Deviation,11.2
NCT00149227,B2,Non-ARB,TRUE,Non-ARB,,,Age,,years,Mean,66.1,Standard Deviation,10.9
NCT00149227,B3,Total,FALSE,,,,Age,,years,Mean,65.9,Standard Deviation,11.1
NCT00149227,B1,Valsartan,TRUE,Valsartan,Male,,Gender,,participants,Number,861,,NA
NCT00149227,B1,Valsartan,TRUE,Valsartan,Female,,Gender,,participants,Number,656,,NA
NCT00149227,B2,Non-ARB,TRUE,Non-ARB,Male,,Gender,,participants,Number,867,,NA
NCT00149227,B2,Non-ARB,TRUE,Non-ARB,Female,,Gender,,participants,Number,647,,NA
NCT00149227,B3,Total,FALSE,,Male,,Gender,,participants,Number,1728,,NA
NCT00149227,B3,Total,FALSE,,Female,,Gender,,participants,Number,1303,,NA
NCT00219141,B1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,,,Age,,years,Mean,58.4,Standard Deviation,9.61
NCT00219141,B2,Losartan 100 mg,TRUE,Losartan 100 mg,,,Age,,years,Mean,59.2,Standard Deviation,11.00
NCT00219141,B3,Aliskiren/Losartan 300/100 mg,FALSE,,,,Age,,years,Mean,58.8,Standard Deviation,10.62
NCT00219141,B4,Total,FALSE,,,,Age,,years,Mean,58.8,Standard Deviation,10.41
NCT00219141,B1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,Male,,Gender,,participants,Number,112,,NA
NCT00219141,B1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,Female,,Gender,,participants,Number,42,,NA
NCT00219141,B2,Losartan 100 mg,TRUE,Losartan 100 mg,Male,,Gender,,participants,Number,117,,NA
NCT00219141,B2,Losartan 100 mg,TRUE,Losartan 100 mg,Female,,Gender,,participants,Number,35,,NA
NCT00219141,B3,Aliskiren/Losartan 300/100 mg,FALSE,,Male,,Gender,,participants,Number,119,,NA
NCT00219141,B3,Aliskiren/Losartan 300/100 mg,FALSE,,Female,,Gender,,participants,Number,35,,NA
NCT00219141,B4,Total,FALSE,,Male,,Gender,,participants,Number,348,,NA
NCT00219141,B4,Total,FALSE,,Female,,Gender,,participants,Number,112,,NA
NCT00281580,B1,Placebo (Pl),FALSE,,,,Age,,Years,Mean,52.5,Standard Deviation,12.3
NCT00281580,B10,Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10),FALSE,,,,Age,,Years,Mean,53.3,Standard Deviation,11.3
NCT00281580,B11,Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5),FALSE,,,,Age,,Years,Mean,54.8,Standard Deviation,9.7
NCT00281580,B12,Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5),FALSE,,,,Age,,Years,Mean,52.7,Standard Deviation,11.9
NCT00281580,B13,Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10),FALSE,,,,Age,,Years,Mean,53.9,Standard Deviation,11.6
NCT00281580,B14,Amlodipine 2.5 mg (A2.5),FALSE,,,,Age,,Years,Mean,55.3,Standard Deviation,10.4
NCT00281580,B15,Amlodipine 5 mg (A5),FALSE,,,,Age,,Years,Mean,53.1,Standard Deviation,10.6
NCT00281580,B16,Amlodipine 10 mg (A10),FALSE,,,,Age,,Years,Mean,53.4,Standard Deviation,10.7
NCT00281580,B17,Total,FALSE,,,,Age,,Years,Mean,53.1,Standard Deviation,11.1
NCT00281580,B2,Telmisartan 20 mg (T20),FALSE,,,,Age,,Years,Mean,53.6,Standard Deviation,10.4
NCT00281580,B3,Telmisartan 40 mg (T40),FALSE,,,,Age,,Years,Mean,52,Standard Deviation,11
NCT00281580,B4,Telmisartan 80 mg (T80),FALSE,,,,Age,,Years,Mean,53.1,Standard Deviation,11.3
NCT00281580,B5,Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5),FALSE,,,,Age,,Years,Mean,54,Standard Deviation,10.8
NCT00281580,B6,Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5),FALSE,,,,Age,,Years,Mean,54.4,Standard Deviation,10.2
NCT00281580,B7,Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10),FALSE,,,,Age,,Years,Mean,51,Standard Deviation,11.2
NCT00281580,B8,Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5),FALSE,,,,Age,,Years,Mean,50.7,Standard Deviation,10.2
NCT00281580,B9,Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5),FALSE,,,,Age,,Years,Mean,52.3,Standard Deviation,11.9
NCT00281580,B1,Placebo (Pl),FALSE,,Male,,Gender,,Participants,Number,29,,NA
NCT00281580,B1,Placebo (Pl),FALSE,,Female,,Gender,,Participants,Number,17,,NA
NCT00281580,B10,Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10),FALSE,,Female,,Gender,,Participants,Number,67,,NA
NCT00281580,B10,Telmisartan 40 mg Plus Amlodipine 10 mg (T40+A10),FALSE,,Male,,Gender,,Participants,Number,62,,NA
NCT00281580,B11,Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5),FALSE,,Female,,Gender,,Participants,Number,26,,NA
NCT00281580,B11,Telmisartan 80 mg Plus Amlodipine 2.5 mg (T80+A2.5),FALSE,,Male,,Gender,,Participants,Number,22,,NA
NCT00281580,B12,Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5),FALSE,,Female,,Gender,,Participants,Number,72,,NA
NCT00281580,B12,Telmisartan 80 mg Plus Amlodipine 5 mg (T80+A5),FALSE,,Male,,Gender,,Participants,Number,74,,NA
NCT00281580,B13,Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10),FALSE,,Female,,Gender,,Participants,Number,78,,NA
NCT00281580,B13,Telmisartan 80 mg Plus Amlodipine 10 mg (T80+A10),FALSE,,Male,,Gender,,Participants,Number,64,,NA
NCT00281580,B14,Amlodipine 2.5 mg (A2.5),FALSE,,Male,,Gender,,Participants,Number,27,,NA
NCT00281580,B14,Amlodipine 2.5 mg (A2.5),FALSE,,Female,,Gender,,Participants,Number,23,,NA
NCT00281580,B15,Amlodipine 5 mg (A5),FALSE,,Male,,Gender,,Participants,Number,72,,NA
NCT00281580,B15,Amlodipine 5 mg (A5),FALSE,,Female,,Gender,,Participants,Number,68,,NA
NCT00281580,B16,Amlodipine 10 mg (A10),FALSE,,Male,,Gender,,Participants,Number,65,,NA
NCT00281580,B16,Amlodipine 10 mg (A10),FALSE,,Female,,Gender,,Participants,Number,64,,NA
NCT00281580,B17,Total,FALSE,,Male,,Gender,,Participants,Number,737,,NA
NCT00281580,B17,Total,FALSE,,Female,,Gender,,Participants,Number,724,,NA
NCT00281580,B2,Telmisartan 20 mg (T20),FALSE,,Male,,Gender,,Participants,Number,26,,NA
NCT00281580,B2,Telmisartan 20 mg (T20),FALSE,,Female,,Gender,,Participants,Number,16,,NA
NCT00281580,B3,Telmisartan 40 mg (T40),FALSE,,Male,,Gender,,Participants,Number,66,,NA
NCT00281580,B3,Telmisartan 40 mg (T40),FALSE,,Female,,Gender,,Participants,Number,64,,NA
NCT00281580,B4,Telmisartan 80 mg (T80),FALSE,,Male,,Gender,,Participants,Number,60,,NA
NCT00281580,B4,Telmisartan 80 mg (T80),FALSE,,Female,,Gender,,Participants,Number,75,,NA
NCT00281580,B5,Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5),FALSE,,Male,,Gender,,Participants,Number,26,,NA
NCT00281580,B5,Telmisartan 20 mg Plus Amlodipine 2.5 mg (T20+A2.5),FALSE,,Female,,Gender,,Participants,Number,18,,NA
NCT00281580,B6,Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5),FALSE,,Male,,Gender,,Participants,Number,21,,NA
NCT00281580,B6,Telmisartan 20 mg Plus Amlodipine 5 mg (T20+A5),FALSE,,Female,,Gender,,Participants,Number,25,,NA
NCT00281580,B7,Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10),FALSE,,Male,,Gender,,Participants,Number,26,,NA
NCT00281580,B7,Telmisartan 20 mg Plus Amlodipine 10 mg (T20+A10),FALSE,,Female,,Gender,,Participants,Number,18,,NA
NCT00281580,B8,Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5),FALSE,,Male,,Gender,,Participants,Number,26,,NA
NCT00281580,B8,Telmisartan 40 mg Plus Amlodipine 2.5 mg (T40+A2.5),FALSE,,Female,,Gender,,Participants,Number,21,,NA
NCT00281580,B9,Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5),FALSE,,Male,,Gender,,Participants,Number,71,,NA
NCT00281580,B9,Telmisartan 40 mg Plus Amlodipine 5 mg (T40+A5),FALSE,,Female,,Gender,,Participants,Number,72,,NA
NCT00368277,B1,Aliskiren Based Treatment Regimen,FALSE,,,,Age,,years,Mean,72.0,Standard Deviation,5.56
NCT00368277,B2,Ramipril Based Treatment Regimen,FALSE,,,,Age,,years,Mean,72.2,Standard Deviation,5.62
NCT00368277,B3,Total,FALSE,,,,Age,,years,Mean,72.1,Standard Deviation,5.58
NCT00368277,B1,Aliskiren Based Treatment Regimen,FALSE,,75 years and older,,"Age, Customized",,participants,Number,145,,NA
NCT00368277,B1,Aliskiren Based Treatment Regimen,FALSE,,65 - 74 years,,"Age, Customized",,participants,Number,312,,NA
NCT00368277,B2,Ramipril Based Treatment Regimen,FALSE,,75 years and older,,"Age, Customized",,participants,Number,148,,NA
NCT00368277,B2,Ramipril Based Treatment Regimen,FALSE,,65 - 74 years,,"Age, Customized",,participants,Number,296,,NA
NCT00368277,B3,Total,FALSE,,75 years and older,,"Age, Customized",,participants,Number,293,,NA
NCT00368277,B3,Total,FALSE,,65 - 74 years,,"Age, Customized",,participants,Number,608,,NA
NCT00368277,B1,Aliskiren Based Treatment Regimen,FALSE,,Male,,Gender,,participants,Number,222,,NA
NCT00368277,B1,Aliskiren Based Treatment Regimen,FALSE,,Female,,Gender,,participants,Number,235,,NA
NCT00368277,B2,Ramipril Based Treatment Regimen,FALSE,,Male,,Gender,,participants,Number,207,,NA
NCT00368277,B2,Ramipril Based Treatment Regimen,FALSE,,Female,,Gender,,participants,Number,237,,NA
NCT00368277,B3,Total,FALSE,,Male,,Gender,,participants,Number,429,,NA
NCT00368277,B3,Total,FALSE,,Female,,Gender,,participants,Number,472,,NA
NCT00413049,B1,Valsartan/Amlodipine 80/5 mg,FALSE,,,,Age,,years,Mean,53.4,Standard Deviation,9.7
NCT00413049,B2,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,,,Age,,years,Mean,54.2,Standard Deviation,9.1
NCT00413049,B3,Total,FALSE,,,,Age,,years,Mean,53.8,Standard Deviation,9.4
NCT00413049,B1,Valsartan/Amlodipine 80/5 mg,FALSE,,Male,,Gender,,participants,Number,213,,NA
NCT00413049,B1,Valsartan/Amlodipine 80/5 mg,FALSE,,Female,,Gender,,participants,Number,134,,NA
NCT00413049,B2,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,Male,,Gender,,participants,Number,240,,NA
NCT00413049,B2,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,Female,,Gender,,participants,Number,109,,NA
NCT00413049,B3,Total,FALSE,,Male,,Gender,,participants,Number,453,,NA
NCT00413049,B3,Total,FALSE,,Female,,Gender,,participants,Number,243,,NA
NCT00413413,B1,Valsartan/Amlodipine 80/5 mg,FALSE,,,,Age,All baseline measures were based on Full-set analysis population. Two patients were excluded from the full-set analysis population for having no post-baseline efficacy assessment. All randomized patients were included in the safety population.,years,Mean,51.6,Standard Deviation,10.8
NCT00413413,B2,Valsartan 80 mg,TRUE,Valsartan 80 mg,,,Age,All baseline measures were based on Full-set analysis population. Two patients were excluded from the full-set analysis population for having no post-baseline efficacy assessment. All randomized patients were included in the safety population.,years,Mean,51.7,Standard Deviation,8.9
NCT00413413,B3,Valsartan 160 mg,TRUE,Valsartan 160 mg,,,Age,All baseline measures were based on Full-set analysis population. Two patients were excluded from the full-set analysis population for having no post-baseline efficacy assessment. All randomized patients were included in the safety population.,years,Mean,51.2,Standard Deviation,9.6
NCT00413413,B4,Total,FALSE,,,,Age,All baseline measures were based on Full-set analysis population. Two patients were excluded from the full-set analysis population for having no post-baseline efficacy assessment. All randomized patients were included in the safety population.,years,Mean,51.5,Standard Deviation,9.8
NCT00413413,B1,Valsartan/Amlodipine 80/5 mg,FALSE,,Male,,Gender,,participants,Number,181,,NA
NCT00413413,B1,Valsartan/Amlodipine 80/5 mg,FALSE,,Female,,Gender,,participants,Number,127,,NA
NCT00413413,B2,Valsartan 80 mg,TRUE,Valsartan 80 mg,Male,,Gender,,participants,Number,191,,NA
NCT00413413,B2,Valsartan 80 mg,TRUE,Valsartan 80 mg,Female,,Gender,,participants,Number,115,,NA
NCT00413413,B3,Valsartan 160 mg,TRUE,Valsartan 160 mg,Male,,Gender,,participants,Number,198,,NA
NCT00413413,B3,Valsartan 160 mg,TRUE,Valsartan 160 mg,Female,,Gender,,participants,Number,104,,NA
NCT00413413,B4,Total,FALSE,,Male,,Gender,,participants,Number,570,,NA
NCT00413413,B4,Total,FALSE,,Female,,Gender,,participants,Number,346,,NA
NCT00425373,B1,Valsartan + Amlodipine 40/2.5 mg,FALSE,,,,Age,,years,Mean,53.9,Standard Deviation,10.34
NCT00425373,B10,Total,FALSE,,,,Age,,years,Mean,53.1,Standard Deviation,10.57
NCT00425373,B2,Valsartan + Amlodipine 40/5 mg,FALSE,,,,Age,,years,Mean,52.8,Standard Deviation,10.70
NCT00425373,B3,Valsartan + Amlodipine 80/2.5 mg,FALSE,,,,Age,,years,Mean,52.8,Standard Deviation,10.76
NCT00425373,B4,Valsartan + Amlodipine 80/5 mg,FALSE,,,,Age,,years,Mean,54.1,Standard Deviation,9.75
NCT00425373,B5,Valsartan 40 mg,TRUE,Valsartan 40 mg,,,Age,,years,Mean,52.9,Standard Deviation,10.08
NCT00425373,B6,Valsartan 80 mg,TRUE,Valsartan 80 mg,,,Age,,years,Mean,52.6,Standard Deviation,11.29
NCT00425373,B7,Amlodipine 2.5 mg,TRUE,Amlodipine 2.5 mg,,,Age,,years,Mean,53.2,Standard Deviation,10.83
NCT00425373,B8,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,,,Age,,years,Mean,54.4,Standard Deviation,10.67
NCT00425373,B9,Placebo,TRUE,Placebo,,,Age,,years,Mean,51.5,Standard Deviation,10.58
NCT00425373,B1,Valsartan + Amlodipine 40/2.5 mg,FALSE,,Male,,Gender,,Participants,Number,113,,NA
NCT00425373,B1,Valsartan + Amlodipine 40/2.5 mg,FALSE,,Female,,Gender,,Participants,Number,46,,NA
NCT00425373,B10,Total,FALSE,,Male,,Gender,,Participants,Number,1063,,NA
NCT00425373,B10,Total,FALSE,,Female,,Gender,,Participants,Number,405,,NA
NCT00425373,B2,Valsartan + Amlodipine 40/5 mg,FALSE,,Male,,Gender,,Participants,Number,118,,NA
NCT00425373,B2,Valsartan + Amlodipine 40/5 mg,FALSE,,Female,,Gender,,Participants,Number,49,,NA
NCT00425373,B3,Valsartan + Amlodipine 80/2.5 mg,FALSE,,Male,,Gender,,Participants,Number,120,,NA
NCT00425373,B3,Valsartan + Amlodipine 80/2.5 mg,FALSE,,Female,,Gender,,Participants,Number,40,,NA
NCT00425373,B4,Valsartan + Amlodipine 80/5 mg,FALSE,,Male,,Gender,,Participants,Number,123,,NA
NCT00425373,B4,Valsartan + Amlodipine 80/5 mg,FALSE,,Female,,Gender,,Participants,Number,39,,NA
NCT00425373,B5,Valsartan 40 mg,TRUE,Valsartan 40 mg,Male,,Gender,,Participants,Number,131,,NA
NCT00425373,B5,Valsartan 40 mg,TRUE,Valsartan 40 mg,Female,,Gender,,Participants,Number,38,,NA
NCT00425373,B6,Valsartan 80 mg,TRUE,Valsartan 80 mg,Male,,Gender,,Participants,Number,114,,NA
NCT00425373,B6,Valsartan 80 mg,TRUE,Valsartan 80 mg,Female,,Gender,,Participants,Number,49,,NA
NCT00425373,B7,Amlodipine 2.5 mg,TRUE,Amlodipine 2.5 mg,Male,,Gender,,Participants,Number,112,,NA
NCT00425373,B7,Amlodipine 2.5 mg,TRUE,Amlodipine 2.5 mg,Female,,Gender,,Participants,Number,49,,NA
NCT00425373,B8,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,Male,,Gender,,Participants,Number,121,,NA
NCT00425373,B8,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,Female,,Gender,,Participants,Number,40,,NA
NCT00425373,B9,Placebo,TRUE,Placebo,Male,,Gender,,Participants,Number,111,,NA
NCT00425373,B9,Placebo,TRUE,Placebo,Female,,Gender,,Participants,Number,55,,NA
NCT00439738,B1,Valsartan/HCTZ (Hydrochlorothiazide),FALSE,,>=65 years,,"Age, Customized",,participants,Number,34,,16.5
NCT00439738,B1,Valsartan/HCTZ (Hydrochlorothiazide),FALSE,,< 65 years,,"Age, Customized",,participants,Number,172,,83.5
NCT00439738,B2,HCTZ +Amlodipine,TRUE,HCTZ +Amlodipine,>=65 years,,"Age, Customized",,participants,Number,26,,12.6
NCT00439738,B2,HCTZ +Amlodipine,TRUE,HCTZ +Amlodipine,< 65 years,,"Age, Customized",,participants,Number,180,,87.4
NCT00439738,B3,Total,FALSE,,>=65 years,,"Age, Customized",,participants,Number,60,,14.6
NCT00439738,B3,Total,FALSE,,< 65 years,,"Age, Customized",,participants,Number,352,,85.4
NCT00439738,B1,Valsartan/HCTZ (Hydrochlorothiazide),FALSE,,,Male,"Sex: Female, Male",,Participants,Count of Participants,82,,NA
NCT00439738,B1,Valsartan/HCTZ (Hydrochlorothiazide),FALSE,,,Female,"Sex: Female, Male",,Participants,Count of Participants,124,,NA
NCT00439738,B2,HCTZ +Amlodipine,TRUE,HCTZ +Amlodipine,,Male,"Sex: Female, Male",,Participants,Count of Participants,58,,NA
NCT00439738,B2,HCTZ +Amlodipine,TRUE,HCTZ +Amlodipine,,Female,"Sex: Female, Male",,Participants,Count of Participants,148,,NA
NCT00439738,B3,Total,FALSE,,,Male,"Sex: Female, Male",,Participants,Count of Participants,140,,NA
NCT00439738,B3,Total,FALSE,,,Female,"Sex: Female, Male",,Participants,Count of Participants,272,,NA
NCT00529451,B1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,,,Age,,years,Mean,53.8,Standard Deviation,9.45
NCT00529451,B2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,,,Age,,years,Mean,53.3,Standard Deviation,10.53
NCT00529451,B3,Aliskiren 75 mg,TRUE,Aliskiren 75 mg,,,Age,,years,Mean,52.7,Standard Deviation,10.22
NCT00529451,B4,Ramipril 5 mg,TRUE,Ramipril 5 mg,,,Age,,years,Mean,52.9,Standard Deviation,9.60
NCT00529451,B5,Total,FALSE,,,,Age,,years,Mean,53.2,Standard Deviation,9.95
NCT00529451,B1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,â‰¥ 65 years,,"Age, Customized",,Participants,Number,43,,NA
NCT00529451,B1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,< 65 years,,"Age, Customized",,Participants,Number,288,,NA
NCT00529451,B2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,â‰¥ 65 years,,"Age, Customized",,Participants,Number,50,,NA
NCT00529451,B2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,< 65 years,,"Age, Customized",,Participants,Number,273,,NA
NCT00529451,B3,Aliskiren 75 mg,TRUE,Aliskiren 75 mg,â‰¥ 65 years,,"Age, Customized",,Participants,Number,47,,NA
NCT00529451,B3,Aliskiren 75 mg,TRUE,Aliskiren 75 mg,< 65 years,,"Age, Customized",,Participants,Number,285,,NA
NCT00529451,B4,Ramipril 5 mg,TRUE,Ramipril 5 mg,â‰¥ 65 years,,"Age, Customized",,Participants,Number,34,,NA
NCT00529451,B4,Ramipril 5 mg,TRUE,Ramipril 5 mg,< 65 years,,"Age, Customized",,Participants,Number,296,,NA
NCT00529451,B5,Total,FALSE,,â‰¥ 65 years,,"Age, Customized",,Participants,Number,174,,NA
NCT00529451,B5,Total,FALSE,,< 65 years,,"Age, Customized",,Participants,Number,1142,,NA
NCT00529451,B1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,Male,,Gender,,participants,Number,181,,NA
NCT00529451,B1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,Female,,Gender,,participants,Number,150,,NA
NCT00529451,B2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,Male,,Gender,,participants,Number,183,,NA
NCT00529451,B2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,Female,,Gender,,participants,Number,140,,NA
NCT00529451,B3,Aliskiren 75 mg,TRUE,Aliskiren 75 mg,Male,,Gender,,participants,Number,188,,NA
NCT00529451,B3,Aliskiren 75 mg,TRUE,Aliskiren 75 mg,Female,,Gender,,participants,Number,144,,NA
NCT00529451,B4,Ramipril 5 mg,TRUE,Ramipril 5 mg,Male,,Gender,,participants,Number,179,,NA
NCT00529451,B4,Ramipril 5 mg,TRUE,Ramipril 5 mg,Female,,Gender,,participants,Number,151,,NA
NCT00529451,B5,Total,FALSE,,Male,,Gender,,participants,Number,731,,NA
NCT00529451,B5,Total,FALSE,,Female,,Gender,,participants,Number,585,,NA
NCT00546754,B1,Losartan 50 mg/HCTZ 12.5 mg,FALSE,,,,Age,,years,Mean,58.7,Standard Deviation,11.11
NCT00546754,B2,Valsartan 80 mg/HCTZ 12.5 mg,FALSE,,,,Age,,years,Mean,58.3,Standard Deviation,10.26
NCT00546754,B3,Total,FALSE,,,,Age,,years,Mean,58.5,Standard Deviation,10.71
NCT00546754,B1,Losartan 50 mg/HCTZ 12.5 mg,FALSE,,,Male,"Sex: Female, Male",,Participants,Count of Participants,219,,NA
NCT00546754,B1,Losartan 50 mg/HCTZ 12.5 mg,FALSE,,,Female,"Sex: Female, Male",,Participants,Count of Participants,197,,NA
NCT00546754,B2,Valsartan 80 mg/HCTZ 12.5 mg,FALSE,,,Male,"Sex: Female, Male",,Participants,Count of Participants,193,,NA
NCT00546754,B2,Valsartan 80 mg/HCTZ 12.5 mg,FALSE,,,Female,"Sex: Female, Male",,Participants,Count of Participants,180,,NA
NCT00546754,B3,Total,FALSE,,,Male,"Sex: Female, Male",,Participants,Count of Participants,412,,NA
NCT00546754,B3,Total,FALSE,,,Female,"Sex: Female, Male",,Participants,Count of Participants,377,,NA
NCT00550953,B1,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,FALSE,,,,Age,,years,Mean,55.4,Standard Deviation,9.1
NCT00550953,B2,Telmisartan 40 mg Monotherapy,FALSE,,,,Age,,years,Mean,55.5,Standard Deviation,10.2
NCT00550953,B3,Total,FALSE,,,,Age,,years,Mean,55.5,Standard Deviation,9.6
NCT00550953,B1,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,FALSE,,Male,,Gender,,participants,Number,114,,NA
NCT00550953,B1,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,FALSE,,Female,,Gender,,participants,Number,42,,NA
NCT00550953,B2,Telmisartan 40 mg Monotherapy,FALSE,,Male,,Gender,,participants,Number,123,,NA
NCT00550953,B2,Telmisartan 40 mg Monotherapy,FALSE,,Female,,Gender,,participants,Number,35,,NA
NCT00550953,B3,Total,FALSE,,Male,,Gender,,participants,Number,237,,NA
NCT00550953,B3,Total,FALSE,,Female,,Gender,,participants,Number,77,,NA
NCT00553267,B1,Amlodipine 10mg,FALSE,,,,Age,,Years,Mean,56.4,Standard Deviation,10.4
NCT00553267,B2,Telmisartan 40mg and Amlodipine 10mg,FALSE,,,,Age,,Years,Mean,57.6,Standard Deviation,9.4
NCT00553267,B3,Telmisartan 80mg and Amlodipine 10mg,FALSE,,,,Age,,Years,Mean,55.5,Standard Deviation,9.8
NCT00553267,B4,Total,FALSE,,,,Age,,Years,Mean,56.5,Standard Deviation,9.9
NCT00553267,B1,Amlodipine 10mg,FALSE,,Male,,Gender,,Number of participants,Number,187,,NA
NCT00553267,B1,Amlodipine 10mg,FALSE,,Female,,Gender,,Number of participants,Number,128,,NA
NCT00553267,B2,Telmisartan 40mg and Amlodipine 10mg,FALSE,,Male,,Gender,,Number of participants,Number,170,,NA
NCT00553267,B2,Telmisartan 40mg and Amlodipine 10mg,FALSE,,Female,,Gender,,Number of participants,Number,145,,NA
NCT00553267,B3,Telmisartan 80mg and Amlodipine 10mg,FALSE,,Male,,Gender,,Number of participants,Number,171,,NA
NCT00553267,B3,Telmisartan 80mg and Amlodipine 10mg,FALSE,,Female,,Gender,,Number of participants,Number,146,,NA
NCT00553267,B4,Total,FALSE,,Male,,Gender,,Number of participants,Number,528,,NA
NCT00553267,B4,Total,FALSE,,Female,,Gender,,Number of participants,Number,419,,NA
NCT00558064,B1,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,FALSE,,,,Age,,years,Mean,57,Standard Deviation,9.6
NCT00558064,B2,Amlodipine 5 mg Monotherapy,FALSE,,,,Age,,years,Mean,56,Standard Deviation,9.9
NCT00558064,B3,Total,FALSE,,,,Age,,years,Mean,56.5,Standard Deviation,9.7
NCT00558064,B1,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,FALSE,,Male,,Gender,,participants,Number,197,,NA
NCT00558064,B1,Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination,FALSE,,Female,,Gender,,participants,Number,72,,NA
NCT00558064,B2,Amlodipine 5 mg Monotherapy,FALSE,,Male,,Gender,,participants,Number,186,,NA
NCT00558064,B2,Amlodipine 5 mg Monotherapy,FALSE,,Female,,Gender,,participants,Number,76,,NA
NCT00558064,B3,Total,FALSE,,Male,,Gender,,participants,Number,383,,NA
NCT00558064,B3,Total,FALSE,,Female,,Gender,,participants,Number,148,,NA
NCT00558428,B1,Amlodipine 5mg,FALSE,,,,Age,,Years,Mean,54,Standard Deviation,10.6
NCT00558428,B2,Amlodipine 10mg,FALSE,,,,Age,,Years,Mean,54.3,Standard Deviation,10.6
NCT00558428,B3,Telmisartan 40mg and Amlodipine 5mg,FALSE,,,,Age,,Years,Mean,53.9,Standard Deviation,11
NCT00558428,B4,Telmisartan 80mg and Amlodipine 5mg,FALSE,,,,Age,,Years,Mean,54.5,Standard Deviation,10.2
NCT00558428,B5,Total,FALSE,,,,Age,,Years,Mean,54.2,Standard Deviation,10.6
NCT00558428,B1,Amlodipine 5mg,FALSE,,Male,,Gender,,participants,Number,163,,NA
NCT00558428,B1,Amlodipine 5mg,FALSE,,Female,,Gender,,participants,Number,104,,NA
NCT00558428,B2,Amlodipine 10mg,FALSE,,Male,,Gender,,participants,Number,176,,NA
NCT00558428,B2,Amlodipine 10mg,FALSE,,Female,,Gender,,participants,Number,100,,NA
NCT00558428,B3,Telmisartan 40mg and Amlodipine 5mg,FALSE,,Male,,Gender,,participants,Number,160,,NA
NCT00558428,B3,Telmisartan 40mg and Amlodipine 5mg,FALSE,,Female,,Gender,,participants,Number,117,,NA
NCT00558428,B4,Telmisartan 80mg and Amlodipine 5mg,FALSE,,Male,,Gender,,participants,Number,183,,NA
NCT00558428,B4,Telmisartan 80mg and Amlodipine 5mg,FALSE,,Female,,Gender,,participants,Number,94,,NA
NCT00558428,B5,Total,FALSE,,Male,,Gender,,participants,Number,682,,NA
NCT00558428,B5,Total,FALSE,,Female,,Gender,,participants,Number,415,,NA
NCT00591578,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,â‰¥65 years (Open Label Phase),,"Age, Customized",,participants,Number,20,,NA
NCT00591578,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,Between 45 and 64 years (Open Label Phase),,"Age, Customized",,participants,Number,25,,NA
NCT00591578,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,<45 years (Open Label Phase),,"Age, Customized",,participants,Number,10,,NA
NCT00591578,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,â‰¥65 years (Double Blind Phase),,"Age, Customized",,participants,Number,103,,NA
NCT00591578,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,Between 45 and 64 years (Double Blind Phase),,"Age, Customized",,participants,Number,181,,NA
NCT00591578,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,<45 years (Double Blind Phase),,"Age, Customized",,participants,Number,43,,NA
NCT00591578,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,â‰¥65 years (Open Label Phase),,"Age, Customized",,participants,Number,39,,NA
NCT00591578,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,Between 45 and 64 years (Open Label Phase),,"Age, Customized",,participants,Number,68,,NA
NCT00591578,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,<45 years (Open Label Phase),,"Age, Customized",,participants,Number,8,,NA
NCT00591578,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,â‰¥65 years (Double Blind Phase),,"Age, Customized",,participants,Number,82,,NA
NCT00591578,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,Between 45 and 64 years (Double Blind Phase),,"Age, Customized",,participants,Number,208,,NA
NCT00591578,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,<45 years (Double Blind Phase),,"Age, Customized",,participants,Number,39,,NA
NCT00591578,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,â‰¥65 years (Open Label Phase),,"Age, Customized",,participants,Number,0,,NA
NCT00591578,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,Between 45 and 64 years (Open Label Phase),,"Age, Customized",,participants,Number,0,,NA
NCT00591578,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,<45 years (Open Label Phase),,"Age, Customized",,participants,Number,0,,NA
NCT00591578,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,â‰¥65 years (Double Blind Phase),,"Age, Customized",,participants,Number,98,,NA
NCT00591578,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,Between 45 and 64 years (Double Blind Phase),,"Age, Customized",,participants,Number,199,,NA
NCT00591578,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,<45 years (Double Blind Phase),,"Age, Customized",,participants,Number,31,,NA
NCT00591578,B4,Total,FALSE,,â‰¥65 years (Open Label Phase),,"Age, Customized",,participants,Number,59,,NA
NCT00591578,B4,Total,FALSE,,Between 45 and 64 years (Open Label Phase),,"Age, Customized",,participants,Number,93,,NA
NCT00591578,B4,Total,FALSE,,<45 years (Open Label Phase),,"Age, Customized",,participants,Number,18,,NA
NCT00591578,B4,Total,FALSE,,â‰¥65 years (Double Blind Phase),,"Age, Customized",,participants,Number,283,,NA
NCT00591578,B4,Total,FALSE,,Between 45 and 64 years (Double Blind Phase),,"Age, Customized",,participants,Number,588,,NA
NCT00591578,B4,Total,FALSE,,<45 years (Double Blind Phase),,"Age, Customized",,participants,Number,113,,NA
NCT00591578,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,Male (Open Label Phase),,"Gender, Customized",,participants,Number,21,,NA
NCT00591578,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,Female (Open Label Phase),,"Gender, Customized",,participants,Number,34,,NA
NCT00591578,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,Male (Double Blind Phase),,"Gender, Customized",,participants,Number,164,,NA
NCT00591578,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,Female (Double Blind Phase),,"Gender, Customized",,participants,Number,163,,NA
NCT00591578,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,Male (Open Label Phase),,"Gender, Customized",,participants,Number,58,,NA
NCT00591578,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,Female (Open Label Phase),,"Gender, Customized",,participants,Number,57,,NA
NCT00591578,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,Male (Double Blind Phase),,"Gender, Customized",,participants,Number,169,,NA
NCT00591578,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,Female (Double Blind Phase),,"Gender, Customized",,participants,Number,160,,NA
NCT00591578,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,Male (Open Label Phase),,"Gender, Customized",,participants,Number,0,,NA
NCT00591578,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,Female (Open Label Phase),,"Gender, Customized",,participants,Number,0,,NA
NCT00591578,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,Male (Double Blind Phase),,"Gender, Customized",,participants,Number,176,,NA
NCT00591578,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,Female (Double Blind Phase),,"Gender, Customized",,participants,Number,152,,NA
NCT00591578,B4,Total,FALSE,,Male (Open Label Phase),,"Gender, Customized",,participants,Number,79,,NA
NCT00591578,B4,Total,FALSE,,Female (Open Label Phase),,"Gender, Customized",,participants,Number,91,,NA
NCT00591578,B4,Total,FALSE,,Male (Double Blind Phase),,"Gender, Customized",,participants,Number,509,,NA
NCT00591578,B4,Total,FALSE,,Female (Double Blind Phase),,"Gender, Customized",,participants,Number,475,,NA
NCT00614380,B1,Telmisartan 40mg and Amlodipine 5mg,FALSE,,,,Age,,Years,Mean,54.8,Standard Deviation,10.9
NCT00614380,B2,Telmisartan 80mg and Amlodipine 5mg,FALSE,,,,Age,,Years,Mean,52.9,Standard Deviation,10.6
NCT00614380,B3,Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive,FALSE,,,,Age,,Years,Mean,54.4,Standard Deviation,10.8
NCT00614380,B4,Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive,FALSE,,,,Age,,Years,Mean,52.4,Standard Deviation,9.6
NCT00614380,B5,Total,FALSE,,,,Age,,Years,Mean,53.9,Standard Deviation,10.6
NCT00614380,B1,Telmisartan 40mg and Amlodipine 5mg,FALSE,,Male,,Gender,,participants,Number,324,,NA
NCT00614380,B1,Telmisartan 40mg and Amlodipine 5mg,FALSE,,Female,,Gender,,participants,Number,240,,NA
NCT00614380,B2,Telmisartan 80mg and Amlodipine 5mg,FALSE,,Male,,Gender,,participants,Number,134,,NA
NCT00614380,B2,Telmisartan 80mg and Amlodipine 5mg,FALSE,,Female,,Gender,,participants,Number,72,,NA
NCT00614380,B3,Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive,FALSE,,Male,,Gender,,participants,Number,17,,NA
NCT00614380,B3,Telmisartan 40mg and Amlodipine 5mg + add-on Antihypertensive,FALSE,,Female,,Gender,,participants,Number,8,,NA
NCT00614380,B4,Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive,FALSE,,Male,,Gender,,participants,Number,136,,NA
NCT00614380,B4,Telmisartan 80mg and Amlodipine 5mg + add-on Antihypertensive,FALSE,,Female,,Gender,,participants,Number,45,,NA
NCT00614380,B5,Total,FALSE,,Male,,Gender,,participants,Number,611,,NA
NCT00614380,B5,Total,FALSE,,Female,,Gender,,participants,Number,365,,NA
NCT00624052,B1,Telmisartan 40mg and Amlodipine 10mg,FALSE,,,,Age,,Years,Mean,56.2,Standard Deviation,9.9
NCT00624052,B2,Randomised Telmisartan 80mg and Amlodipine 10mg,FALSE,,,,Age,,Years,Mean,57.3,Standard Deviation,9.4
NCT00624052,B3,Titrated Telmisartan 80mg and Amlodipine 10mg,FALSE,,,,Age,,Years,Mean,55.2,Standard Deviation,9.7
NCT00624052,B4,Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on,FALSE,,,,Age,,Years,Mean,53.3,Standard Deviation,10.3
NCT00624052,B5,Total,FALSE,,,,Age,,Years,Mean,56.4,Standard Deviation,9.7
NCT00624052,B1,Telmisartan 40mg and Amlodipine 10mg,FALSE,,Male,,Gender,,Participants,Number,126,,NA
NCT00624052,B1,Telmisartan 40mg and Amlodipine 10mg,FALSE,,Female,,Gender,,Participants,Number,93,,NA
NCT00624052,B2,Randomised Telmisartan 80mg and Amlodipine 10mg,FALSE,,Male,,Gender,,Participants,Number,230,,NA
NCT00624052,B2,Randomised Telmisartan 80mg and Amlodipine 10mg,FALSE,,Female,,Gender,,Participants,Number,206,,NA
NCT00624052,B3,Titrated Telmisartan 80mg and Amlodipine 10mg,FALSE,,Male,,Gender,,Participants,Number,60,,NA
NCT00624052,B3,Titrated Telmisartan 80mg and Amlodipine 10mg,FALSE,,Female,,Gender,,Participants,Number,31,,NA
NCT00624052,B4,Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on,FALSE,,Male,,Gender,,Participants,Number,55,,NA
NCT00624052,B4,Telmisartan 40mg or 80mg and Amlodipine 10mg + add-on,FALSE,,Female,,Gender,,Participants,Number,37,,NA
NCT00624052,B5,Total,FALSE,,Male,,Gender,,Participants,Number,471,,NA
NCT00624052,B5,Total,FALSE,,Female,,Gender,,Participants,Number,367,,NA
NCT00631917,B1,Aliskiren,TRUE,Aliskiren,,,Age,,years,Mean,59.3,Standard Deviation,6.99
NCT00631917,B2,Ramipril,TRUE,Ramipril,,,Age,,years,Mean,59.3,Standard Deviation,6.65
NCT00631917,B3,Total,FALSE,,,,Age,,years,Mean,59.3,Standard Deviation,6.81
NCT00631917,B1,Aliskiren,TRUE,Aliskiren,65 years and greater,,"Age, Customized",,Participants,Number,76,,NA
NCT00631917,B1,Aliskiren,TRUE,Aliskiren,< 65 years,,"Age, Customized",,Participants,Number,299,,NA
NCT00631917,B2,Ramipril,TRUE,Ramipril,65 years and greater,,"Age, Customized",,Participants,Number,86,,NA
NCT00631917,B2,Ramipril,TRUE,Ramipril,< 65 years,,"Age, Customized",,Participants,Number,313,,NA
NCT00631917,B3,Total,FALSE,,65 years and greater,,"Age, Customized",,Participants,Number,162,,NA
NCT00631917,B3,Total,FALSE,,< 65 years,,"Age, Customized",,Participants,Number,612,,NA
NCT00631917,B1,Aliskiren,TRUE,Aliskiren,Male,,Gender,,participants,Number,181,,NA
NCT00631917,B1,Aliskiren,TRUE,Aliskiren,Female,,Gender,,participants,Number,194,,NA
NCT00631917,B2,Ramipril,TRUE,Ramipril,Male,,Gender,,participants,Number,205,,NA
NCT00631917,B2,Ramipril,TRUE,Ramipril,Female,,Gender,,participants,Number,194,,NA
NCT00631917,B3,Total,FALSE,,Male,,Gender,,participants,Number,386,,NA
NCT00631917,B3,Total,FALSE,,Female,,Gender,,participants,Number,388,,NA
NCT00649389,B1,OM40/AML10,TRUE,OM40/AML10,,,Age,,years,Mean,55.1,Standard Deviation,10.93
NCT00649389,B1,OM40/AML10,TRUE,OM40/AML10,>=65 years,,Age,,participants,Number,120,,NA
NCT00649389,B1,OM40/AML10,TRUE,OM40/AML10,Between 18 and 65 years,,Age,,participants,Number,508,,NA
NCT00649389,B1,OM40/AML10,TRUE,OM40/AML10,<=18 years,,Age,,participants,Number,0,,NA
NCT00649389,B2,OM40/HCTZ25,TRUE,OM40/HCTZ25,,,Age,,years,Mean,55.9,Standard Deviation,10.78
NCT00649389,B2,OM40/HCTZ25,TRUE,OM40/HCTZ25,>=65 years,,Age,,participants,Number,132,,NA
NCT00649389,B2,OM40/HCTZ25,TRUE,OM40/HCTZ25,Between 18 and 65 years,,Age,,participants,Number,505,,NA
NCT00649389,B2,OM40/HCTZ25,TRUE,OM40/HCTZ25,<=18 years,,Age,,participants,Number,0,,NA
NCT00649389,B3,AML10/HCTZ25,TRUE,AML10/HCTZ25,,,Age,,years,Mean,54.6,Standard Deviation,10.82
NCT00649389,B3,AML10/HCTZ25,TRUE,AML10/HCTZ25,>=65 years,,Age,,participants,Number,96,,NA
NCT00649389,B3,AML10/HCTZ25,TRUE,AML10/HCTZ25,Between 18 and 65 years,,Age,,participants,Number,504,,NA
NCT00649389,B3,AML10/HCTZ25,TRUE,AML10/HCTZ25,<=18 years,,Age,,participants,Number,0,,NA
NCT00649389,B4,OM40/AML10/HCTZ25,TRUE,OM40/AML10/HCTZ25,>=65 years,,Age,,participants,Number,123,,NA
NCT00649389,B4,OM40/AML10/HCTZ25,TRUE,OM40/AML10/HCTZ25,,,Age,,years,Mean,54.7,Standard Deviation,11.22
NCT00649389,B4,OM40/AML10/HCTZ25,TRUE,OM40/AML10/HCTZ25,Between 18 and 65 years,,Age,,participants,Number,504,,NA
NCT00649389,B4,OM40/AML10/HCTZ25,TRUE,OM40/AML10/HCTZ25,<=18 years,,Age,,participants,Number,0,,NA
NCT00649389,B5,Total,FALSE,,>=65 years,,Age,,participants,Number,471,,NA
NCT00649389,B5,Total,FALSE,,,,Age,,years,Mean,55.1,Standard Deviation,10.94
NCT00649389,B5,Total,FALSE,,Between 18 and 65 years,,Age,,participants,Number,2021,,NA
NCT00649389,B5,Total,FALSE,,<=18 years,,Age,,participants,Number,0,,NA
NCT00649389,B1,OM40/AML10,TRUE,OM40/AML10,Greater than or equal to 30 kg/m2,,Body Mass Index,,Participants,Number,399,,NA
NCT00649389,B1,OM40/AML10,TRUE,OM40/AML10,Less than 30 kg/m2,,Body Mass Index,,Participants,Number,229,,NA
NCT00649389,B2,OM40/HCTZ25,TRUE,OM40/HCTZ25,Greater than or equal to 30 kg/m2,,Body Mass Index,,Participants,Number,399,,NA
NCT00649389,B2,OM40/HCTZ25,TRUE,OM40/HCTZ25,Less than 30 kg/m2,,Body Mass Index,,Participants,Number,238,,NA
NCT00649389,B3,AML10/HCTZ25,TRUE,AML10/HCTZ25,Greater than or equal to 30 kg/m2,,Body Mass Index,,Participants,Number,370,,NA
NCT00649389,B3,AML10/HCTZ25,TRUE,AML10/HCTZ25,Less than 30 kg/m2,,Body Mass Index,,Participants,Number,230,,NA
NCT00649389,B4,OM40/AML10/HCTZ25,TRUE,OM40/AML10/HCTZ25,Greater than or equal to 30 kg/m2,,Body Mass Index,,Participants,Number,387,,NA
NCT00649389,B4,OM40/AML10/HCTZ25,TRUE,OM40/AML10/HCTZ25,Less than 30 kg/m2,,Body Mass Index,,Participants,Number,240,,NA
NCT00649389,B5,Total,FALSE,,Greater than or equal to 30 kg/m2,,Body Mass Index,,Participants,Number,1555,,NA
NCT00649389,B5,Total,FALSE,,Less than 30 kg/m2,,Body Mass Index,,Participants,Number,937,,NA
NCT00649389,B1,OM40/AML10,TRUE,OM40/AML10,Male,,Gender,,participants,Number,325,,NA
NCT00649389,B1,OM40/AML10,TRUE,OM40/AML10,Female,,Gender,,participants,Number,303,,NA
NCT00649389,B2,OM40/HCTZ25,TRUE,OM40/HCTZ25,Male,,Gender,,participants,Number,339,,NA
NCT00649389,B2,OM40/HCTZ25,TRUE,OM40/HCTZ25,Female,,Gender,,participants,Number,298,,NA
NCT00649389,B3,AML10/HCTZ25,TRUE,AML10/HCTZ25,Male,,Gender,,participants,Number,334,,NA
NCT00649389,B3,AML10/HCTZ25,TRUE,AML10/HCTZ25,Female,,Gender,,participants,Number,266,,NA
NCT00649389,B4,OM40/AML10/HCTZ25,TRUE,OM40/AML10/HCTZ25,Male,,Gender,,participants,Number,320,,NA
NCT00649389,B4,OM40/AML10/HCTZ25,TRUE,OM40/AML10/HCTZ25,Female,,Gender,,participants,Number,307,,NA
NCT00649389,B5,Total,FALSE,,Male,,Gender,,participants,Number,1318,,NA
NCT00649389,B5,Total,FALSE,,Female,,Gender,,participants,Number,1174,,NA
NCT00687973,B1,Valsartan/Amlodipine 160/10 mg,FALSE,,,,Age,,years,Mean,57.5,Standard Deviation,9.94
NCT00687973,B2,Atenolol/Amlodipine 100/10 mg,FALSE,,,,Age,,years,Mean,56.2,Standard Deviation,11.09
NCT00687973,B3,Total,FALSE,,,,Age,,years,Mean,56.9,Standard Deviation,10.55
NCT00687973,B1,Valsartan/Amlodipine 160/10 mg,FALSE,,Male,,Gender,,participants,Number,111,,NA
NCT00687973,B1,Valsartan/Amlodipine 160/10 mg,FALSE,,Female,,Gender,,participants,Number,82,,NA
NCT00687973,B2,Atenolol/Amlodipine 100/10 mg,FALSE,,Male,,Gender,,participants,Number,99,,NA
NCT00687973,B2,Atenolol/Amlodipine 100/10 mg,FALSE,,Female,,Gender,,participants,Number,101,,NA
NCT00687973,B3,Total,FALSE,,Male,,Gender,,participants,Number,210,,NA
NCT00687973,B3,Total,FALSE,,Female,,Gender,,participants,Number,183,,NA
NCT00696241,B1,Azilsartan Medoxomil 20 mg QD,TRUE,Azilsartan Medoxomil 20 mg QD,â‰¥65 years,,Age,,participants,Number,78,,NA
NCT00696241,B1,Azilsartan Medoxomil 20 mg QD,TRUE,Azilsartan Medoxomil 20 mg QD,Between 45 and 64 years,,Age,,participants,Number,173,,NA
NCT00696241,B1,Azilsartan Medoxomil 20 mg QD,TRUE,Azilsartan Medoxomil 20 mg QD,<45 years,,Age,,participants,Number,32,,NA
NCT00696241,B2,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,â‰¥65 years,,Age,,participants,Number,67,,NA
NCT00696241,B2,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,Between 45 and 64 years,,Age,,participants,Number,187,,NA
NCT00696241,B2,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,<45 years,,Age,,participants,Number,29,,NA
NCT00696241,B3,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,â‰¥65 years,,Age,,participants,Number,87,,NA
NCT00696241,B3,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,Between 45 and 64 years,,Age,,participants,Number,161,,NA
NCT00696241,B3,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,<45 years,,Age,,participants,Number,37,,NA
NCT00696241,B4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,â‰¥65 years,,Age,,participants,Number,97,,NA
NCT00696241,B4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,Between 45 and 64 years,,Age,,participants,Number,153,,NA
NCT00696241,B4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,<45 years,,Age,,participants,Number,32,,NA
NCT00696241,B5,Placebo QD,TRUE,Placebo QD,â‰¥65 years,,Age,,participants,Number,47,,NA
NCT00696241,B5,Placebo QD,TRUE,Placebo QD,Between 45 and 64 years,,Age,,participants,Number,84,,NA
NCT00696241,B5,Placebo QD,TRUE,Placebo QD,<45 years,,Age,,participants,Number,11,,NA
NCT00696241,B6,Total,FALSE,,â‰¥65 years,,Age,,participants,Number,376,,NA
NCT00696241,B6,Total,FALSE,,Between 45 and 64 years,,Age,,participants,Number,758,,NA
NCT00696241,B6,Total,FALSE,,<45 years,,Age,,participants,Number,141,,NA
NCT00696241,B1,Azilsartan Medoxomil 20 mg QD,TRUE,Azilsartan Medoxomil 20 mg QD,Male,,Gender,,participants,Number,133,,NA
NCT00696241,B1,Azilsartan Medoxomil 20 mg QD,TRUE,Azilsartan Medoxomil 20 mg QD,Female,,Gender,,participants,Number,150,,NA
NCT00696241,B2,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,Male,,Gender,,participants,Number,142,,NA
NCT00696241,B2,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,Female,,Gender,,participants,Number,141,,NA
NCT00696241,B3,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,Male,,Gender,,participants,Number,149,,NA
NCT00696241,B3,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,Female,,Gender,,participants,Number,136,,NA
NCT00696241,B4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,Male,,Gender,,participants,Number,140,,NA
NCT00696241,B4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,Female,,Gender,,participants,Number,142,,NA
NCT00696241,B5,Placebo QD,TRUE,Placebo QD,Male,,Gender,,participants,Number,76,,NA
NCT00696241,B5,Placebo QD,TRUE,Placebo QD,Female,,Gender,,participants,Number,66,,NA
NCT00696241,B6,Total,FALSE,,Male,,Gender,,participants,Number,640,,NA
NCT00696241,B6,Total,FALSE,,Female,,Gender,,participants,Number,635,,NA
NCT00696436,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,â‰¥65 years,,Age,,participants,Number,69,,NA
NCT00696436,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,Between 45 and 64 years,,Age,,participants,Number,170,,NA
NCT00696436,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,<45 years,,Age,,participants,Number,41,,NA
NCT00696436,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,â‰¥65 years,,Age,,participants,Number,63,,NA
NCT00696436,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,Between 45 and 64 years,,Age,,participants,Number,184,,NA
NCT00696436,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,<45 years,,Age,,participants,Number,38,,NA
NCT00696436,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,â‰¥65 years,,Age,,participants,Number,48,,NA
NCT00696436,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,Between 45 and 64 years,,Age,,participants,Number,178,,NA
NCT00696436,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,<45 years,,Age,,participants,Number,56,,NA
NCT00696436,B4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,â‰¥65 years,,Age,,participants,Number,66,,NA
NCT00696436,B4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,Between 45 and 64 years,,Age,,participants,Number,185,,NA
NCT00696436,B4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,<45 years,,Age,,participants,Number,39,,NA
NCT00696436,B5,Placebo QD,TRUE,Placebo QD,â‰¥65 years,,Age,,participants,Number,36,,NA
NCT00696436,B5,Placebo QD,TRUE,Placebo QD,Between 45 and 64 years,,Age,,participants,Number,98,,NA
NCT00696436,B5,Placebo QD,TRUE,Placebo QD,<45 years,,Age,,participants,Number,20,,NA
NCT00696436,B6,Total,FALSE,,â‰¥65 years,,Age,,participants,Number,282,,NA
NCT00696436,B6,Total,FALSE,,Between 45 and 64 years,,Age,,participants,Number,815,,NA
NCT00696436,B6,Total,FALSE,,<45 years,,Age,,participants,Number,194,,NA
NCT00696436,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,Male,,Gender,,participants,Number,147,,NA
NCT00696436,B1,Azilsartan Medoxomil 40 mg QD,TRUE,Azilsartan Medoxomil 40 mg QD,Female,,Gender,,participants,Number,133,,NA
NCT00696436,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,Male,,Gender,,participants,Number,151,,NA
NCT00696436,B2,Azilsartan Medoxomil 80 mg QD,TRUE,Azilsartan Medoxomil 80 mg QD,Female,,Gender,,participants,Number,134,,NA
NCT00696436,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,Male,,Gender,,participants,Number,152,,NA
NCT00696436,B3,Valsartan 320 mg QD,TRUE,Valsartan 320 mg QD,Female,,Gender,,participants,Number,130,,NA
NCT00696436,B4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,Male,,Gender,,participants,Number,159,,NA
NCT00696436,B4,Olmesartan 40 mg QD,TRUE,Olmesartan 40 mg QD,Female,,Gender,,participants,Number,131,,NA
NCT00696436,B5,Placebo QD,TRUE,Placebo QD,Male,,Gender,,participants,Number,90,,NA
NCT00696436,B5,Placebo QD,TRUE,Placebo QD,Female,,Gender,,participants,Number,64,,NA
NCT00696436,B6,Total,FALSE,,Male,,Gender,,participants,Number,699,,NA
NCT00696436,B6,Total,FALSE,,Female,,Gender,,participants,Number,592,,NA
NCT00698646,B1,Valsartan,TRUE,Valsartan,,,Age,,years,Mean,77.7,Standard Deviation,4.22
NCT00698646,B2,HCTZ,TRUE,HCTZ,,,Age,,years,Mean,77.7,Standard Deviation,4.80
NCT00698646,B3,Valsartan + HCTZ,TRUE,Valsartan + HCTZ,,,Age,,years,Mean,77.2,Standard Deviation,3.99
NCT00698646,B4,Total,FALSE,,,,Age,,years,Mean,77.5,Standard Deviation,4.34
NCT00698646,B1,Valsartan,TRUE,Valsartan,>80 years,,"Age, Customized",,participants,Number,27,,NA
NCT00698646,B1,Valsartan,TRUE,Valsartan,76-80 years,,"Age, Customized",,participants,Number,60,,NA
NCT00698646,B1,Valsartan,TRUE,Valsartan,70-75 years,,"Age, Customized",,participants,Number,41,,NA
NCT00698646,B2,HCTZ,TRUE,HCTZ,>80 years,,"Age, Customized",,participants,Number,31,,NA
NCT00698646,B2,HCTZ,TRUE,HCTZ,76-80 years,,"Age, Customized",,participants,Number,56,,NA
NCT00698646,B2,HCTZ,TRUE,HCTZ,70-75 years,,"Age, Customized",,participants,Number,41,,NA
NCT00698646,B3,Valsartan + HCTZ,TRUE,Valsartan + HCTZ,>80 years,,"Age, Customized",,participants,Number,19,,NA
NCT00698646,B3,Valsartan + HCTZ,TRUE,Valsartan + HCTZ,76-80 years,,"Age, Customized",,participants,Number,65,,NA
NCT00698646,B3,Valsartan + HCTZ,TRUE,Valsartan + HCTZ,70-75 years,,"Age, Customized",,participants,Number,44,,NA
NCT00698646,B4,Total,FALSE,,>80 years,,"Age, Customized",,participants,Number,77,,NA
NCT00698646,B4,Total,FALSE,,76-80 years,,"Age, Customized",,participants,Number,181,,NA
NCT00698646,B4,Total,FALSE,,70-75 years,,"Age, Customized",,participants,Number,126,,NA
NCT00698646,B1,Valsartan,TRUE,Valsartan,Male,,Gender,,participants,Number,47,,NA
NCT00698646,B1,Valsartan,TRUE,Valsartan,Female,,Gender,,participants,Number,81,,NA
NCT00698646,B2,HCTZ,TRUE,HCTZ,Male,,Gender,,participants,Number,66,,NA
NCT00698646,B2,HCTZ,TRUE,HCTZ,Female,,Gender,,participants,Number,62,,NA
NCT00698646,B3,Valsartan + HCTZ,TRUE,Valsartan + HCTZ,Male,,Gender,,participants,Number,57,,NA
NCT00698646,B3,Valsartan + HCTZ,TRUE,Valsartan + HCTZ,Female,,Gender,,participants,Number,71,,NA
NCT00698646,B4,Total,FALSE,,Male,,Gender,,participants,Number,170,,NA
NCT00698646,B4,Total,FALSE,,Female,,Gender,,participants,Number,214,,NA
NCT00699192,B1,Amlodipine/Valsartan 5/80 mg,TRUE,Amlodipine/Valsartan 5/80 mg,,,Age,,years,Mean,71.8,Standard Deviation,5.01
NCT00699192,B2,Amlodipine/Valsartan 5/40 mg,TRUE,Amlodipine/Valsartan 5/40 mg,,,Age,,years,Mean,71.6,Standard Deviation,5.38
NCT00699192,B3,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,,,Age,,years,Mean,71.4,Standard Deviation,5.44
NCT00699192,B4,Total,FALSE,,,,Age,,years,Mean,71.6,Standard Deviation,5.27
NCT00699192,B1,Amlodipine/Valsartan 5/80 mg,TRUE,Amlodipine/Valsartan 5/80 mg,Male,,Gender,,participants,Number,123,,NA
NCT00699192,B1,Amlodipine/Valsartan 5/80 mg,TRUE,Amlodipine/Valsartan 5/80 mg,Female,,Gender,,participants,Number,152,,NA
NCT00699192,B2,Amlodipine/Valsartan 5/40 mg,TRUE,Amlodipine/Valsartan 5/40 mg,Male,,Gender,,participants,Number,134,,NA
NCT00699192,B2,Amlodipine/Valsartan 5/40 mg,TRUE,Amlodipine/Valsartan 5/40 mg,Female,,Gender,,participants,Number,138,,NA
NCT00699192,B3,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,Male,,Gender,,participants,Number,130,,NA
NCT00699192,B3,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,Female,,Gender,,participants,Number,142,,NA
NCT00699192,B4,Total,FALSE,,Male,,Gender,,participants,Number,387,,NA
NCT00699192,B4,Total,FALSE,,Female,,Gender,,participants,Number,432,,NA
NCT00705575,B1,Aliskiren/Hydrochlorothiazide (HCTZ) (300/25 mg),FALSE,,,,Age,,years,Mean,57.4,Standard Deviation,10.33
NCT00705575,B2,Aliskiren (300 mg),TRUE,Aliskiren (300 mg),,,Age,,years,Mean,56.4,Standard Deviation,10.73
NCT00705575,B3,Total,FALSE,,,,Age,,years,Mean,56.9,Standard Deviation,10.53
NCT00705575,B1,Aliskiren/Hydrochlorothiazide (HCTZ) (300/25 mg),FALSE,,Male,,Gender,,participants,Number,180,,NA
NCT00705575,B1,Aliskiren/Hydrochlorothiazide (HCTZ) (300/25 mg),FALSE,,Female,,Gender,,participants,Number,169,,NA
NCT00705575,B2,Aliskiren (300 mg),TRUE,Aliskiren (300 mg),Male,,Gender,,participants,Number,167,,NA
NCT00705575,B2,Aliskiren (300 mg),TRUE,Aliskiren (300 mg),Female,,Gender,,participants,Number,172,,NA
NCT00705575,B3,Total,FALSE,,Male,,Gender,,participants,Number,347,,NA
NCT00705575,B3,Total,FALSE,,Female,,Gender,,participants,Number,341,,NA
NCT00706134,B1,Placebo,TRUE,Placebo,â‰¥ 75 years of age,,"Age, Customized",,Participants,Number,61,,NA
NCT00706134,B1,Placebo,TRUE,Placebo,â‰¥ 65 and < 75 years of age,,"Age, Customized",,Participants,Number,128,,NA
NCT00706134,B2,Aliskiren 75 mg,TRUE,Aliskiren 75 mg,â‰¥ 75 years of age,,"Age, Customized",,Participants,Number,61,,NA
NCT00706134,B2,Aliskiren 75 mg,TRUE,Aliskiren 75 mg,â‰¥ 65 and < 75 years of age,,"Age, Customized",,Participants,Number,131,,NA
NCT00706134,B3,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,â‰¥ 75 years of age,,"Age, Customized",,Participants,Number,60,,NA
NCT00706134,B3,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,â‰¥ 65 and < 75 years of age,,"Age, Customized",,Participants,Number,129,,NA
NCT00706134,B4,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,â‰¥ 75 years of age,,"Age, Customized",,Participants,Number,57,,NA
NCT00706134,B4,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,â‰¥ 65 and < 75 years of age,,"Age, Customized",,Participants,Number,129,,NA
NCT00706134,B5,Total,FALSE,,â‰¥ 75 years of age,,"Age, Customized",,Participants,Number,239,,NA
NCT00706134,B5,Total,FALSE,,â‰¥ 65 and < 75 years of age,,"Age, Customized",,Participants,Number,517,,NA
NCT00706134,B1,Placebo,TRUE,Placebo,Male,,Gender,,Participants,Number,89,,NA
NCT00706134,B1,Placebo,TRUE,Placebo,Female,,Gender,,Participants,Number,100,,NA
NCT00706134,B2,Aliskiren 75 mg,TRUE,Aliskiren 75 mg,Male,,Gender,,Participants,Number,83,,NA
NCT00706134,B2,Aliskiren 75 mg,TRUE,Aliskiren 75 mg,Female,,Gender,,Participants,Number,109,,NA
NCT00706134,B3,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,Male,,Gender,,Participants,Number,83,,NA
NCT00706134,B3,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,Female,,Gender,,Participants,Number,106,,NA
NCT00706134,B4,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,Male,,Gender,,Participants,Number,84,,NA
NCT00706134,B4,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,Female,,Gender,,Participants,Number,102,,NA
NCT00706134,B5,Total,FALSE,,Male,,Gender,,Participants,Number,339,,NA
NCT00706134,B5,Total,FALSE,,Female,,Gender,,Participants,Number,417,,NA
NCT00739973,B1,Placebo,TRUE,Placebo,,,Age,,years,Mean,53.7,Standard Deviation,10.32
NCT00739973,B10,Total,FALSE,,,,Age,,years,Mean,54.1,Standard Deviation,10.65
NCT00739973,B2,Aliskiren 150 mg,FALSE,,,,Age,,years,Mean,54.3,Standard Deviation,11.07
NCT00739973,B3,Aliskiren 300 mg,FALSE,,,,Age,,years,Mean,54.0,Standard Deviation,9.99
NCT00739973,B4,Amlodipine 5 mg,FALSE,,,,Age,,years,Mean,54.2,Standard Deviation,11.61
NCT00739973,B5,Amlodipine 10 mg,FALSE,,,,Age,,years,Mean,55.0,Standard Deviation,10.34
NCT00739973,B6,Aliskiren/Amlodipine 150/5 mg,FALSE,,,,Age,,years,Mean,53.9,Standard Deviation,10.82
NCT00739973,B7,Aliskiren/Amlodipine 150/10 mg,FALSE,,,,Age,,years,Mean,53.0,Standard Deviation,10.59
NCT00739973,B8,Aliskiren/Amlodipine 300/5 mg,FALSE,,,,Age,,years,Mean,54.8,Standard Deviation,10.29
NCT00739973,B9,Aliskiren/Amlodipine 300/10 mg Tablet,FALSE,,,,Age,,years,Mean,54.4,Standard Deviation,10.86
NCT00739973,B1,Placebo,TRUE,Placebo,Male,,Gender,,participants,Number,90,,NA
NCT00739973,B1,Placebo,TRUE,Placebo,Female,,Gender,,participants,Number,108,,NA
NCT00739973,B10,Total,FALSE,,Male,,Gender,,participants,Number,858,,NA
NCT00739973,B10,Total,FALSE,,Female,,Gender,,participants,Number,830,,NA
NCT00739973,B2,Aliskiren 150 mg,FALSE,,Male,,Gender,,participants,Number,119,,NA
NCT00739973,B2,Aliskiren 150 mg,FALSE,,Female,,Gender,,participants,Number,76,,NA
NCT00739973,B3,Aliskiren 300 mg,FALSE,,Male,,Gender,,participants,Number,95,,NA
NCT00739973,B3,Aliskiren 300 mg,FALSE,,Female,,Gender,,participants,Number,108,,NA
NCT00739973,B4,Amlodipine 5 mg,FALSE,,Male,,Gender,,participants,Number,99,,NA
NCT00739973,B4,Amlodipine 5 mg,FALSE,,Female,,Gender,,participants,Number,86,,NA
NCT00739973,B5,Amlodipine 10 mg,FALSE,,Male,,Gender,,participants,Number,87,,NA
NCT00739973,B5,Amlodipine 10 mg,FALSE,,Female,,Gender,,participants,Number,94,,NA
NCT00739973,B6,Aliskiren/Amlodipine 150/5 mg,FALSE,,Male,,Gender,,participants,Number,97,,NA
NCT00739973,B6,Aliskiren/Amlodipine 150/5 mg,FALSE,,Female,,Gender,,participants,Number,84,,NA
NCT00739973,B7,Aliskiren/Amlodipine 150/10 mg,FALSE,,Male,,Gender,,participants,Number,87,,NA
NCT00739973,B7,Aliskiren/Amlodipine 150/10 mg,FALSE,,Female,,Gender,,participants,Number,96,,NA
NCT00739973,B8,Aliskiren/Amlodipine 300/5 mg,FALSE,,Male,,Gender,,participants,Number,78,,NA
NCT00739973,B8,Aliskiren/Amlodipine 300/5 mg,FALSE,,Female,,Gender,,participants,Number,100,,NA
NCT00739973,B9,Aliskiren/Amlodipine 300/10 mg Tablet,FALSE,,Male,,Gender,,participants,Number,106,,NA
NCT00739973,B9,Aliskiren/Amlodipine 300/10 mg Tablet,FALSE,,Female,,Gender,,participants,Number,78,,NA
NCT00760266,B1,Aliskiren/HCTZ,FALSE,,,,Age,,years,Mean,64.5,Standard Deviation,7.57
NCT00760266,B2,HCTZ,FALSE,,,,Age,,years,Mean,65.1,Standard Deviation,6.96
NCT00760266,B3,Total,FALSE,,,,Age,,years,Mean,64.8,Standard Deviation,7.27
NCT00760266,B1,Aliskiren/HCTZ,FALSE,,Male,,Gender,,participants,Number,101,,NA
NCT00760266,B1,Aliskiren/HCTZ,FALSE,,Female,,Gender,,participants,Number,127,,NA
NCT00760266,B2,HCTZ,FALSE,,Male,,Gender,,participants,Number,123,,NA
NCT00760266,B2,HCTZ,FALSE,,Female,,Gender,,participants,Number,100,,NA
NCT00760266,B3,Total,FALSE,,Male,,Gender,,participants,Number,224,,NA
NCT00760266,B3,Total,FALSE,,Female,,Gender,,participants,Number,227,,NA
NCT00765674,B1,Aliskiren / Amlodipine,FALSE,,,,Age,,years,Mean,54.4,Standard Deviation,11.33
NCT00765674,B2,Aliskiren / Hydrochlorothiazide,FALSE,,,,Age,,years,Mean,55.5,Standard Deviation,10.75
NCT00765674,B3,Amlodipine / Hydrochlorothiazide,FALSE,,,,Age,,years,Mean,55.1,Standard Deviation,10.86
NCT00765674,B4,Aliskiren / Amlodipine / Hydrochlorothiazide,FALSE,,,,Age,,years,Mean,55.4,Standard Deviation,10.54
NCT00765674,B5,Total,FALSE,,,,Age,,years,Mean,55.1,Standard Deviation,10.86
NCT00765674,B1,Aliskiren / Amlodipine,FALSE,,>=65 years,,"Age, Customized",,participants,Number,50,,NA
NCT00765674,B1,Aliskiren / Amlodipine,FALSE,,< 65 years,,"Age, Customized",,participants,Number,237,,NA
NCT00765674,B2,Aliskiren / Hydrochlorothiazide,FALSE,,>=65 years,,"Age, Customized",,participants,Number,56,,NA
NCT00765674,B2,Aliskiren / Hydrochlorothiazide,FALSE,,< 65 years,,"Age, Customized",,participants,Number,242,,NA
NCT00765674,B3,Amlodipine / Hydrochlorothiazide,FALSE,,>=65 years,,"Age, Customized",,participants,Number,63,,NA
NCT00765674,B3,Amlodipine / Hydrochlorothiazide,FALSE,,< 65 years,,"Age, Customized",,participants,Number,233,,NA
NCT00765674,B4,Aliskiren / Amlodipine / Hydrochlorothiazide,FALSE,,>=65 years,,"Age, Customized",,participants,Number,59,,NA
NCT00765674,B4,Aliskiren / Amlodipine / Hydrochlorothiazide,FALSE,,< 65 years,,"Age, Customized",,participants,Number,251,,NA
NCT00765674,B5,Total,FALSE,,>=65 years,,"Age, Customized",,participants,Number,228,,NA
NCT00765674,B5,Total,FALSE,,< 65 years,,"Age, Customized",,participants,Number,963,,NA
NCT00765674,B1,Aliskiren / Amlodipine,FALSE,,Male,,Gender,,participants,Number,172,,NA
NCT00765674,B1,Aliskiren / Amlodipine,FALSE,,Female,,Gender,,participants,Number,115,,NA
NCT00765674,B2,Aliskiren / Hydrochlorothiazide,FALSE,,Male,,Gender,,participants,Number,175,,NA
NCT00765674,B2,Aliskiren / Hydrochlorothiazide,FALSE,,Female,,Gender,,participants,Number,123,,NA
NCT00765674,B3,Amlodipine / Hydrochlorothiazide,FALSE,,Male,,Gender,,participants,Number,186,,NA
NCT00765674,B3,Amlodipine / Hydrochlorothiazide,FALSE,,Female,,Gender,,participants,Number,110,,NA
NCT00765674,B4,Aliskiren / Amlodipine / Hydrochlorothiazide,FALSE,,Male,,Gender,,participants,Number,187,,NA
NCT00765674,B4,Aliskiren / Amlodipine / Hydrochlorothiazide,FALSE,,Female,,Gender,,participants,Number,123,,NA
NCT00765674,B5,Total,FALSE,,Male,,Gender,,participants,Number,720,,NA
NCT00765674,B5,Total,FALSE,,Female,,Gender,,participants,Number,471,,NA
NCT00777946,B1,Aliskiren 300 mg/Amlodipine 10 mg,TRUE,Aliskiren 300 mg/Amlodipine 10 mg,,,Age,,years,Mean,54.6,Standard Deviation,10.67
NCT00777946,B2,Aliskiren 300 mg/Amlodipine 5 mg,TRUE,Aliskiren 300 mg/Amlodipine 5 mg,,,Age,,years,Mean,54.4,Standard Deviation,10.69
NCT00777946,B3,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,,,Age,,years,Mean,54.7,Standard Deviation,10.99
NCT00777946,B4,Total,FALSE,,,,Age,,years,Mean,54.6,Standard Deviation,10.77
NCT00777946,B1,Aliskiren 300 mg/Amlodipine 10 mg,TRUE,Aliskiren 300 mg/Amlodipine 10 mg,Male,,Gender,,participants,Number,163,,NA
NCT00777946,B1,Aliskiren 300 mg/Amlodipine 10 mg,TRUE,Aliskiren 300 mg/Amlodipine 10 mg,Female,,Gender,,participants,Number,120,,NA
NCT00777946,B2,Aliskiren 300 mg/Amlodipine 5 mg,TRUE,Aliskiren 300 mg/Amlodipine 5 mg,Male,,Gender,,participants,Number,176,,NA
NCT00777946,B2,Aliskiren 300 mg/Amlodipine 5 mg,TRUE,Aliskiren 300 mg/Amlodipine 5 mg,Female,,Gender,,participants,Number,101,,NA
NCT00777946,B3,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,Male,,Gender,,participants,Number,157,,NA
NCT00777946,B3,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,Female,,Gender,,participants,Number,103,,NA
NCT00777946,B4,Total,FALSE,,Male,,Gender,,participants,Number,496,,NA
NCT00777946,B4,Total,FALSE,,Female,,Gender,,participants,Number,324,,NA
NCT00778921,B1,Aliskiren/Amlodipine 300/10 mg,TRUE,Aliskiren/Amlodipine 300/10 mg,,,Age,,years,Mean,55.2,Standard Deviation,10.19
NCT00778921,B2,Aliskiren/Amlodipine 150/10 mg,TRUE,Aliskiren/Amlodipine 150/10 mg,,,Age,,years,Mean,54.4,Standard Deviation,10.70
NCT00778921,B3,Amlodipine 10 mg,TRUE,Amlodipine 10 mg,,,Age,,years,Mean,54.3,Standard Deviation,10.92
NCT00778921,B4,Total,FALSE,,,,Age,,years,Mean,54.6,Standard Deviation,10.60
NCT00778921,B1,Aliskiren/Amlodipine 300/10 mg,TRUE,Aliskiren/Amlodipine 300/10 mg,Male,,Gender,,participants,Number,163,,NA
NCT00778921,B1,Aliskiren/Amlodipine 300/10 mg,TRUE,Aliskiren/Amlodipine 300/10 mg,Female,,Gender,,participants,Number,116,,NA
NCT00778921,B2,Aliskiren/Amlodipine 150/10 mg,TRUE,Aliskiren/Amlodipine 150/10 mg,Male,,Gender,,participants,Number,172,,NA
NCT00778921,B2,Aliskiren/Amlodipine 150/10 mg,TRUE,Aliskiren/Amlodipine 150/10 mg,Female,,Gender,,participants,Number,113,,NA
NCT00778921,B3,Amlodipine 10 mg,TRUE,Amlodipine 10 mg,Male,,Gender,,participants,Number,184,,NA
NCT00778921,B3,Amlodipine 10 mg,TRUE,Amlodipine 10 mg,Female,,Gender,,participants,Number,99,,NA
NCT00778921,B4,Total,FALSE,,Male,,Gender,,participants,Number,519,,NA
NCT00778921,B4,Total,FALSE,,Female,,Gender,,participants,Number,328,,NA
NCT00787605,B1,Aliskiren/HCTZ,FALSE,,,,Age,,years,Mean,59.7,Standard Deviation,9.83
NCT00787605,B2,Amlodipine,TRUE,Amlodipine,,,Age,,years,Mean,59.8,Standard Deviation,10.01
NCT00787605,B3,Total,FALSE,,,,Age,,years,Mean,59.8,Standard Deviation,9.91
NCT00787605,B1,Aliskiren/HCTZ,FALSE,,Male,,Gender,,participants,Number,216,,NA
NCT00787605,B1,Aliskiren/HCTZ,FALSE,,Female,,Gender,,participants,Number,212,,NA
NCT00787605,B2,Amlodipine,TRUE,Amlodipine,Male,,Gender,,participants,Number,223,,NA
NCT00787605,B2,Amlodipine,TRUE,Amlodipine,Female,,Gender,,participants,Number,209,,NA
NCT00787605,B3,Total,FALSE,,Male,,Gender,,participants,Number,439,,NA
NCT00787605,B3,Total,FALSE,,Female,,Gender,,participants,Number,421,,NA
NCT00797316,B1,Aliskiren/HCTZ,FALSE,,,,Age,,years,Mean,54.4,Standard Deviation,11.09
NCT00797316,B2,Aliskiren,TRUE,Aliskiren,,,Age,,years,Mean,53.5,Standard Deviation,10.87
NCT00797316,B3,Total,FALSE,,,,Age,,years,Mean,53.9,Standard Deviation,10.98
NCT00797316,B1,Aliskiren/HCTZ,FALSE,,>= 65,,"Age, Customized",,participants,Number,50,,NA
NCT00797316,B1,Aliskiren/HCTZ,FALSE,,< 65,,"Age, Customized",,participants,Number,217,,NA
NCT00797316,B2,Aliskiren,TRUE,Aliskiren,>= 65,,"Age, Customized",,participants,Number,32,,NA
NCT00797316,B2,Aliskiren,TRUE,Aliskiren,< 65,,"Age, Customized",,participants,Number,233,,NA
NCT00797316,B3,Total,FALSE,,>= 65,,"Age, Customized",,participants,Number,82,,NA
NCT00797316,B3,Total,FALSE,,< 65,,"Age, Customized",,participants,Number,450,,NA
NCT00797316,B1,Aliskiren/HCTZ,FALSE,,Male,,Gender,,participants,Number,139,,NA
NCT00797316,B1,Aliskiren/HCTZ,FALSE,,Female,,Gender,,participants,Number,128,,NA
NCT00797316,B2,Aliskiren,TRUE,Aliskiren,Male,,Gender,,participants,Number,136,,NA
NCT00797316,B2,Aliskiren,TRUE,Aliskiren,Female,,Gender,,participants,Number,129,,NA
NCT00797316,B3,Total,FALSE,,Male,,Gender,,participants,Number,275,,NA
NCT00797316,B3,Total,FALSE,,Female,,Gender,,participants,Number,257,,NA
NCT00809926,B1,Valsartan/Aliskiren,FALSE,,,,Age,,years,Mean,57.5,Standard Deviation,11.1
NCT00809926,B2,Valsartan,TRUE,Valsartan,,,Age,,years,Mean,56.7,Standard Deviation,11.0
NCT00809926,B3,Total,FALSE,,,,Age,,years,Mean,57.1,Standard Deviation,11.0
NCT00809926,B1,Valsartan/Aliskiren,FALSE,,Male,,Gender,,participants,Number,125,,NA
NCT00809926,B1,Valsartan/Aliskiren,FALSE,,Female,,Gender,,participants,Number,107,,NA
NCT00809926,B2,Valsartan,TRUE,Valsartan,Male,,Gender,,participants,Number,103,,NA
NCT00809926,B2,Valsartan,TRUE,Valsartan,Female,,Gender,,participants,Number,116,,NA
NCT00809926,B3,Total,FALSE,,Male,,Gender,,participants,Number,228,,NA
NCT00809926,B3,Total,FALSE,,Female,,Gender,,participants,Number,223,,NA
NCT00841672,B1,Aliskiren/Amlodipine 300/10 mg Tablet,FALSE,,,,Age,,years,Mean,59,Standard Deviation,10.38
NCT00841672,B2,Amlodipine 10 mg Capsule,FALSE,,,,Age,,years,Mean,59,Standard Deviation,10.82
NCT00841672,B3,Total,FALSE,,,,Age,,years,Mean,59,Standard Deviation,10.60
NCT00841672,B1,Aliskiren/Amlodipine 300/10 mg Tablet,FALSE,,Male,,Gender,,participants,Number,108,,NA
NCT00841672,B1,Aliskiren/Amlodipine 300/10 mg Tablet,FALSE,,Female,,Gender,,participants,Number,136,,NA
NCT00841672,B2,Amlodipine 10 mg Capsule,FALSE,,Male,,Gender,,participants,Number,102,,NA
NCT00841672,B2,Amlodipine 10 mg Capsule,FALSE,,Female,,Gender,,participants,Number,139,,NA
NCT00841672,B3,Total,FALSE,,Male,,Gender,,participants,Number,210,,NA
NCT00841672,B3,Total,FALSE,,Female,,Gender,,participants,Number,275,,NA
NCT00846365,B1,Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,,,Age,,years,Mean,55.5,Standard Deviation,10.49
NCT00846365,B2,Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,,,Age,,years,Mean,56.7,Standard Deviation,10.83
NCT00846365,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,FALSE,,,,Age,,years,Mean,55.7,Standard Deviation,9.78
NCT00846365,B4,Total,FALSE,,,,Age,,years,Mean,56.0,Standard Deviation,10.38
NCT00846365,B1,Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,â‰¥65 years,,"Age, Customized",,participants,Number,73,,NA
NCT00846365,B1,Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,45 to 64 years,,"Age, Customized",,participants,Number,252,,NA
NCT00846365,B1,Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,<45 years,,"Age, Customized",,participants,Number,47,,NA
NCT00846365,B2,Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,â‰¥65 years,,"Age, Customized",,participants,Number,75,,NA
NCT00846365,B2,Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,45 to 64 years,,"Age, Customized",,participants,Number,244,,NA
NCT00846365,B2,Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,<45 years,,"Age, Customized",,participants,Number,38,,NA
NCT00846365,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,FALSE,,â‰¥65 years,,"Age, Customized",,participants,Number,66,,NA
NCT00846365,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,FALSE,,45 to 64 years,,"Age, Customized",,participants,Number,249,,NA
NCT00846365,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,FALSE,,<45 years,,"Age, Customized",,participants,Number,41,,NA
NCT00846365,B4,Total,FALSE,,â‰¥65 years,,"Age, Customized",,participants,Number,214,,NA
NCT00846365,B4,Total,FALSE,,45 to 64 years,,"Age, Customized",,participants,Number,745,,NA
NCT00846365,B4,Total,FALSE,,<45 years,,"Age, Customized",,participants,Number,126,,NA
NCT00846365,B1,Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,,,Body Mass Index (BMI),BMI was calculated using height at Screening and weight at Baseline.,kg/m^2,Mean,31.7,Standard Deviation,5.94
NCT00846365,B2,Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,,,Body Mass Index (BMI),BMI was calculated using height at Screening and weight at Baseline.,kg/m^2,Mean,31.8,Standard Deviation,6.40
NCT00846365,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,FALSE,,,,Body Mass Index (BMI),BMI was calculated using height at Screening and weight at Baseline.,kg/m^2,Mean,31.9,Standard Deviation,6.08
NCT00846365,B4,Total,FALSE,,,,Body Mass Index (BMI),BMI was calculated using height at Screening and weight at Baseline.,kg/m^2,Mean,31.8,Standard Deviation,6.14
NCT00846365,B1,Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,Male,,Gender,,participants,Number,197,,NA
NCT00846365,B1,Azilsartan Medoxomil 20-40mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,Female,,Gender,,participants,Number,175,,NA
NCT00846365,B2,Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,Male,,Gender,,participants,Number,183,,NA
NCT00846365,B2,Azilsartan Medoxomil 40-80mg Plus Chlorthalidone 12.5-25 mg QD,FALSE,,Female,,Gender,,participants,Number,174,,NA
NCT00846365,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,FALSE,,Male,,Gender,,participants,Number,183,,NA
NCT00846365,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,FALSE,,Female,,Gender,,participants,Number,173,,NA
NCT00846365,B4,Total,FALSE,,Male,,Gender,,participants,Number,563,,NA
NCT00846365,B4,Total,FALSE,,Female,,Gender,,participants,Number,522,,NA
NCT00853957,B1,Aliskiren/Amlodipine,TRUE,Aliskiren/Amlodipine,,,Age,,years,Mean,53.2,Standard Deviation,9.33
NCT00853957,B2,Amlodipine,TRUE,Amlodipine,,,Age,,years,Mean,52.4,Standard Deviation,10.57
NCT00853957,B3,Total,FALSE,,,,Age,,years,Mean,52.8,Standard Deviation,9.97
NCT00853957,B1,Aliskiren/Amlodipine,TRUE,Aliskiren/Amlodipine,â‰¥55 years,,"Age, Customized",,participants,Number,97,,NA
NCT00853957,B1,Aliskiren/Amlodipine,TRUE,Aliskiren/Amlodipine,<55 years,,"Age, Customized",,participants,Number,123,,NA
NCT00853957,B2,Amlodipine,TRUE,Amlodipine,â‰¥55 years,,"Age, Customized",,participants,Number,96,,NA
NCT00853957,B2,Amlodipine,TRUE,Amlodipine,<55 years,,"Age, Customized",,participants,Number,127,,NA
NCT00853957,B3,Total,FALSE,,â‰¥55 years,,"Age, Customized",,participants,Number,193,,NA
NCT00853957,B3,Total,FALSE,,<55 years,,"Age, Customized",,participants,Number,250,,NA
NCT00853957,B1,Aliskiren/Amlodipine,TRUE,Aliskiren/Amlodipine,Male,,Gender,,participants,Number,97,,NA
NCT00853957,B1,Aliskiren/Amlodipine,TRUE,Aliskiren/Amlodipine,Female,,Gender,,participants,Number,123,,NA
NCT00853957,B2,Amlodipine,TRUE,Amlodipine,Male,,Gender,,participants,Number,108,,NA
NCT00853957,B2,Amlodipine,TRUE,Amlodipine,Female,,Gender,,participants,Number,115,,NA
NCT00853957,B3,Total,FALSE,,Male,,Gender,,participants,Number,205,,NA
NCT00853957,B3,Total,FALSE,,Female,,Gender,,participants,Number,238,,NA
NCT00860262,B1,T80+A10,FALSE,,,,Age,,years,Mean,58.0,Standard Deviation,10.4
NCT00860262,B2,Telmisartan 80 mg,FALSE,,,,Age,,years,Mean,58.1,Standard Deviation,10.2
NCT00860262,B3,Amlodipine 10 mg,FALSE,,,,Age,,years,Mean,58.6,Standard Deviation,10.5
NCT00860262,B4,Total,FALSE,,,,Age,,years,Mean,58.2,Standard Deviation,10.3
NCT00860262,B1,T80+A10,FALSE,,>= 65 years,,"Age, Customized",,Participants,Number,112,,NA
NCT00860262,B1,T80+A10,FALSE,,< 65 years,,"Age, Customized",,Participants,Number,309,,NA
NCT00860262,B2,Telmisartan 80 mg,FALSE,,>= 65 years,,"Age, Customized",,Participants,Number,59,,NA
NCT00860262,B2,Telmisartan 80 mg,FALSE,,< 65 years,,"Age, Customized",,Participants,Number,158,,NA
NCT00860262,B3,Amlodipine 10 mg,FALSE,,>= 65 years,,"Age, Customized",,Participants,Number,64,,NA
NCT00860262,B3,Amlodipine 10 mg,FALSE,,< 65 years,,"Age, Customized",,Participants,Number,156,,NA
NCT00860262,B4,Total,FALSE,,>= 65 years,,"Age, Customized",,Participants,Number,235,,NA
NCT00860262,B4,Total,FALSE,,< 65 years,,"Age, Customized",,Participants,Number,623,,NA
NCT00860262,B1,T80+A10,FALSE,,,,Body Mass Index (BMI),,kilograms/square meter,Mean,30.6,Standard Deviation,5.9
NCT00860262,B2,Telmisartan 80 mg,FALSE,,,,Body Mass Index (BMI),,kilograms/square meter,Mean,30.2,Standard Deviation,5.2
NCT00860262,B3,Amlodipine 10 mg,FALSE,,,,Body Mass Index (BMI),,kilograms/square meter,Mean,30.7,Standard Deviation,6.3
NCT00860262,B4,Total,FALSE,,,,Body Mass Index (BMI),,kilograms/square meter,Mean,30.6,Standard Deviation,5.8
NCT00860262,B1,T80+A10,FALSE,,BMI >= 30,,Body Mass Index Class,,participants,Number,198,,NA
NCT00860262,B1,T80+A10,FALSE,,25 <= BMI < 30,,Body Mass Index Class,,participants,Number,160,,NA
NCT00860262,B1,T80+A10,FALSE,,BMI < 25,,Body Mass Index Class,,participants,Number,63,,NA
NCT00860262,B2,Telmisartan 80 mg,FALSE,,BMI >= 30,,Body Mass Index Class,,participants,Number,107,,NA
NCT00860262,B2,Telmisartan 80 mg,FALSE,,25 <= BMI < 30,,Body Mass Index Class,,participants,Number,79,,NA
NCT00860262,B2,Telmisartan 80 mg,FALSE,,BMI < 25,,Body Mass Index Class,,participants,Number,31,,NA
NCT00860262,B3,Amlodipine 10 mg,FALSE,,BMI >= 30,,Body Mass Index Class,,participants,Number,103,,NA
NCT00860262,B3,Amlodipine 10 mg,FALSE,,25 <= BMI < 30,,Body Mass Index Class,,participants,Number,82,,NA
NCT00860262,B3,Amlodipine 10 mg,FALSE,,BMI < 25,,Body Mass Index Class,,participants,Number,35,,NA
NCT00860262,B4,Total,FALSE,,BMI >= 30,,Body Mass Index Class,,participants,Number,408,,NA
NCT00860262,B4,Total,FALSE,,25 <= BMI < 30,,Body Mass Index Class,,participants,Number,321,,NA
NCT00860262,B4,Total,FALSE,,BMI < 25,,Body Mass Index Class,,participants,Number,129,,NA
NCT00860262,B1,T80+A10,FALSE,,Male,,Gender,,participants,Number,219,,NA
NCT00860262,B1,T80+A10,FALSE,,Female,,Gender,,participants,Number,202,,NA
NCT00860262,B2,Telmisartan 80 mg,FALSE,,Male,,Gender,,participants,Number,108,,NA
NCT00860262,B2,Telmisartan 80 mg,FALSE,,Female,,Gender,,participants,Number,109,,NA
NCT00860262,B3,Amlodipine 10 mg,FALSE,,Male,,Gender,,participants,Number,118,,NA
NCT00860262,B3,Amlodipine 10 mg,FALSE,,Female,,Gender,,participants,Number,102,,NA
NCT00860262,B4,Total,FALSE,,Male,,Gender,,participants,Number,445,,NA
NCT00860262,B4,Total,FALSE,,Female,,Gender,,participants,Number,413,,NA
NCT00865020,B1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,,,Age,,years,Mean,55.8,Standard Deviation,11.46
NCT00865020,B2,Telmisartan 80 mg,TRUE,Telmisartan 80 mg,,,Age,,years,Mean,56.0,Standard Deviation,11.91
NCT00865020,B3,Total,FALSE,,,,Age,,years,Mean,55.9,Standard Deviation,11.68
NCT00865020,B1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,Male,,Gender,,participants,Number,208,,NA
NCT00865020,B1,Aliskiren 300 mg,TRUE,Aliskiren 300 mg,Female,,Gender,,participants,Number,206,,NA
NCT00865020,B2,Telmisartan 80 mg,TRUE,Telmisartan 80 mg,Male,,Gender,,participants,Number,230,,NA
NCT00865020,B2,Telmisartan 80 mg,TRUE,Telmisartan 80 mg,Female,,Gender,,participants,Number,178,,NA
NCT00865020,B3,Total,FALSE,,Male,,Gender,,participants,Number,438,,NA
NCT00865020,B3,Total,FALSE,,Female,,Gender,,participants,Number,384,,NA
NCT00877929,B1,Telmisartan 80 mg + Amlodipine 10 mg,FALSE,,,,Age,,years,Mean,60.5,Standard Deviation,10.4
NCT00877929,B2,Amlodipine 10 mg,FALSE,,,,Age,,years,Mean,60.5,Standard Deviation,9.7
NCT00877929,B3,Total,FALSE,,,,Age,,years,Mean,60.5,Standard Deviation,10.1
NCT00877929,B1,Telmisartan 80 mg + Amlodipine 10 mg,FALSE,,>= 65 years,,"Age, Customized",,participants,Number,138,,NA
NCT00877929,B1,Telmisartan 80 mg + Amlodipine 10 mg,FALSE,,< 65 years,,"Age, Customized",,participants,Number,214,,NA
NCT00877929,B2,Amlodipine 10 mg,FALSE,,>= 65 years,,"Age, Customized",,participants,Number,119,,NA
NCT00877929,B2,Amlodipine 10 mg,FALSE,,< 65 years,,"Age, Customized",,participants,Number,235,,NA
NCT00877929,B3,Total,FALSE,,>= 65 years,,"Age, Customized",,participants,Number,257,,NA
NCT00877929,B3,Total,FALSE,,< 65 years,,"Age, Customized",,participants,Number,449,,NA
NCT00877929,B1,Telmisartan 80 mg + Amlodipine 10 mg,FALSE,,,,Body Mass Index,,kilogram / square meter,Mean,32.1,Standard Deviation,6.0
NCT00877929,B2,Amlodipine 10 mg,FALSE,,,,Body Mass Index,,kilogram / square meter,Mean,31.8,Standard Deviation,6.1
NCT00877929,B3,Total,FALSE,,,,Body Mass Index,,kilogram / square meter,Mean,32.0,Standard Deviation,6.1
NCT00877929,B1,Telmisartan 80 mg + Amlodipine 10 mg,FALSE,,>= 30 kg/square meter,,Body Mass Index Class,,participants,Number,206,,NA
NCT00877929,B1,Telmisartan 80 mg + Amlodipine 10 mg,FALSE,,25 to <30 kg/square meter,,Body Mass Index Class,,participants,Number,114,,NA
NCT00877929,B1,Telmisartan 80 mg + Amlodipine 10 mg,FALSE,,< 25 kg/square meter,,Body Mass Index Class,,participants,Number,32,,NA
NCT00877929,B2,Amlodipine 10 mg,FALSE,,>= 30 kg/square meter,,Body Mass Index Class,,participants,Number,200,,NA
NCT00877929,B2,Amlodipine 10 mg,FALSE,,25 to <30 kg/square meter,,Body Mass Index Class,,participants,Number,123,,NA
NCT00877929,B2,Amlodipine 10 mg,FALSE,,< 25 kg/square meter,,Body Mass Index Class,,participants,Number,31,,NA
NCT00877929,B3,Total,FALSE,,>= 30 kg/square meter,,Body Mass Index Class,,participants,Number,406,,NA
NCT00877929,B3,Total,FALSE,,25 to <30 kg/square meter,,Body Mass Index Class,,participants,Number,237,,NA
NCT00877929,B3,Total,FALSE,,< 25 kg/square meter,,Body Mass Index Class,,participants,Number,63,,NA
NCT00877929,B1,Telmisartan 80 mg + Amlodipine 10 mg,FALSE,,Male,,Gender,,participants,Number,180,,NA
NCT00877929,B1,Telmisartan 80 mg + Amlodipine 10 mg,FALSE,,Female,,Gender,,participants,Number,172,,NA
NCT00877929,B2,Amlodipine 10 mg,FALSE,,Male,,Gender,,participants,Number,185,,NA
NCT00877929,B2,Amlodipine 10 mg,FALSE,,Female,,Gender,,participants,Number,169,,NA
NCT00877929,B3,Total,FALSE,,Male,,Gender,,participants,Number,365,,NA
NCT00877929,B3,Total,FALSE,,Female,,Gender,,participants,Number,341,,NA
NCT00902304,B1,Usual Care,FALSE,,,,Age,,years,Mean,59,Standard Deviation,12
NCT00902304,B2,Monotherapy (Initial Monotherapy Arm),FALSE,,,,Age,,years,Mean,59,Standard Deviation,12
NCT00902304,B3,Combination (Initial Combination Therapy Arm),FALSE,,,,Age,,years,Mean,59,Standard Deviation,12
NCT00902304,B4,Total,FALSE,,,,Age,,years,Mean,59,Standard Deviation,12
NCT00902304,B1,Usual Care,FALSE,,Male,,Gender,,participants,Number,323,,NA
NCT00902304,B1,Usual Care,FALSE,,Female,,Gender,,participants,Number,201,,NA
NCT00902304,B2,Monotherapy (Initial Monotherapy Arm),FALSE,,Male,,Gender,,participants,Number,222,,NA
NCT00902304,B2,Monotherapy (Initial Monotherapy Arm),FALSE,,Female,,Gender,,participants,Number,138,,NA
NCT00902304,B3,Combination (Initial Combination Therapy Arm),FALSE,,Male,,Gender,,participants,Number,418,,NA
NCT00902304,B3,Combination (Initial Combination Therapy Arm),FALSE,,Female,,Gender,,participants,Number,260,,NA
NCT00902304,B4,Total,FALSE,,Male,,Gender,,participants,Number,963,,NA
NCT00902304,B4,Total,FALSE,,Female,,Gender,,participants,Number,599,,NA
NCT00902538,B1,Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg,FALSE,,,,Age,,years,Mean,55.9,Standard Deviation,10.56
NCT00902538,B2,OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5,FALSE,,,,Age,,years,Mean,56.5,Standard Deviation,10.25
NCT00902538,B3,OLM 40-AML 10-HCTZ 25,FALSE,,,,Age,,years,Mean,54.9,Standard Deviation,10.44
NCT00902538,B4,Total,FALSE,,,,Age,,years,Mean,55.8,Standard Deviation,10.42
NCT00902538,B1,Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg,FALSE,,,,Body Mass Index,,kg/m^2,Mean,30.27,Standard Deviation,4.90
NCT00902538,B2,OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5,FALSE,,,,Body Mass Index,,kg/m^2,Mean,30.30,Standard Deviation,4.65
NCT00902538,B3,OLM 40-AML 10-HCTZ 25,FALSE,,,,Body Mass Index,,kg/m^2,Mean,30.44,Standard Deviation,4.87
NCT00902538,B4,Total,FALSE,,,,Body Mass Index,,kg/m^2,Mean,30.34,Standard Deviation,4.80
NCT00902538,B1,Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg,FALSE,,Male,,Gender,,participants,Number,150,,NA
NCT00902538,B1,Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg,FALSE,,Female,,Gender,,participants,Number,119,,NA
NCT00902538,B2,OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5,FALSE,,Male,,Gender,,participants,Number,165,,NA
NCT00902538,B2,OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5,FALSE,,Female,,Gender,,participants,Number,104,,NA
NCT00902538,B3,OLM 40-AML 10-HCTZ 25,FALSE,,Male,,Gender,,participants,Number,154,,NA
NCT00902538,B3,OLM 40-AML 10-HCTZ 25,FALSE,,Female,,Gender,,participants,Number,116,,NA
NCT00902538,B4,Total,FALSE,,Male,,Gender,,participants,Number,469,,NA
NCT00902538,B4,Total,FALSE,,Female,,Gender,,participants,Number,339,,NA
NCT00923091,B1,Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg,FALSE,,,,Age,,years,Mean,56.0,Standard Deviation,10.81
NCT00923091,B2,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg,FALSE,,,,Age,,years,Mean,56.8,Standard Deviation,10.36
NCT00923091,B3,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg,FALSE,,,,Age,,years,Mean,56.5,Standard Deviation,10.92
NCT00923091,B4,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg,FALSE,,,,Age,,years,Mean,57.0,Standard Deviation,10.72
NCT00923091,B5,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg,FALSE,,,,Age,,years,Mean,55.9,Standard Deviation,11.08
NCT00923091,B6,Olmesartan/Amlodipine 20mg/5mg,FALSE,,,,Age,,years,Mean,56.1,Standard Deviation,10.22
NCT00923091,B7,Olmesartan/Amlodipine 40mg/5mg,FALSE,,,,Age,,years,Mean,56.4,Standard Deviation,10.4
NCT00923091,B8,Olmesartan/Amlodipine 40mg/10mg,FALSE,,,,Age,,years,Mean,57.0,Standard Deviation,9.70
NCT00923091,B9,Total,FALSE,,,,Age,,years,Mean,56.5,Standard Deviation,10.53
NCT00923091,B1,Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg,FALSE,,Male,,Gender,,participants,Number,153,,NA
NCT00923091,B1,Olmesartan/Amlodipine/Hydrochlorothiazide 20mg/5mg/12.5 mg,FALSE,,Female,,Gender,,participants,Number,182,,NA
NCT00923091,B2,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg,FALSE,,Male,,Gender,,participants,Number,165,,NA
NCT00923091,B2,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/12.5mg,FALSE,,Female,,Gender,,participants,Number,171,,NA
NCT00923091,B3,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg,FALSE,,Male,,Gender,,participants,Number,152,,NA
NCT00923091,B3,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/5mg/25mg,FALSE,,Female,,Gender,,participants,Number,184,,NA
NCT00923091,B4,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg,FALSE,,Male,,Gender,,participants,Number,155,,NA
NCT00923091,B4,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/12.5mg,FALSE,,Female,,Gender,,participants,Number,181,,NA
NCT00923091,B5,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg,FALSE,,Male,,Gender,,participants,Number,158,,NA
NCT00923091,B5,Olmesartan/Amlodipine/Hydrochlorothiazide 40mg/10mg/25mg,FALSE,,Female,,Gender,,participants,Number,178,,NA
NCT00923091,B6,Olmesartan/Amlodipine 20mg/5mg,FALSE,,Male,,Gender,,participants,Number,152,,NA
NCT00923091,B6,Olmesartan/Amlodipine 20mg/5mg,FALSE,,Female,,Gender,,participants,Number,185,,NA
NCT00923091,B7,Olmesartan/Amlodipine 40mg/5mg,FALSE,,Male,,Gender,,participants,Number,167,,NA
NCT00923091,B7,Olmesartan/Amlodipine 40mg/5mg,FALSE,,Female,,Gender,,participants,Number,170,,NA
NCT00923091,B8,Olmesartan/Amlodipine 40mg/10mg,FALSE,,Male,,Gender,,participants,Number,144,,NA
NCT00923091,B8,Olmesartan/Amlodipine 40mg/10mg,FALSE,,Female,,Gender,,participants,Number,192,,NA
NCT00923091,B9,Total,FALSE,,Male,,Gender,,participants,Number,1246,,NA
NCT00923091,B9,Total,FALSE,,Female,,Gender,,participants,Number,1443,,NA
NCT00926289,B1,Telmisartan 40/80 mg,FALSE,,,,Age,,Years,Mean,57.6,Standard Deviation,11.9
NCT00926289,B2,Telmisartan 40/80 mg + HCTZ 12.5/25 mg,FALSE,,,,Age,,Years,Mean,56.8,Standard Deviation,11.3
NCT00926289,B3,Total,FALSE,,,,Age,,Years,Mean,57.0,Standard Deviation,11.5
NCT00926289,B1,Telmisartan 40/80 mg,FALSE,,Male,,Gender,,Participants,Number,169,,NA
NCT00926289,B1,Telmisartan 40/80 mg,FALSE,,Female,,Gender,,Participants,Number,125,,NA
NCT00926289,B2,Telmisartan 40/80 mg + HCTZ 12.5/25 mg,FALSE,,Male,,Gender,,Participants,Number,309,,NA
NCT00926289,B2,Telmisartan 40/80 mg + HCTZ 12.5/25 mg,FALSE,,Female,,Gender,,Participants,Number,285,,NA
NCT00926289,B3,Total,FALSE,,Male,,Gender,,Participants,Number,478,,NA
NCT00926289,B3,Total,FALSE,,Female,,Gender,,Participants,Number,410,,NA
NCT00927394,B1,Combination Therapy: Aliskiren + Valsartan,TRUE,Combination Therapy: Aliskiren + Valsartan,,,Age,Demographic measures were based on Safety set.,years,Mean,55.0,Standard Deviation,9.30
NCT00927394,B2,Monotherapy: Valsartan,TRUE,Monotherapy: Valsartan,,,Age,Demographic measures were based on Safety set.,years,Mean,55.2,Standard Deviation,9.60
NCT00927394,B3,Total,FALSE,,,,Age,Demographic measures were based on Safety set.,years,Mean,55.1,Standard Deviation,9.44
NCT00927394,B1,Combination Therapy: Aliskiren + Valsartan,TRUE,Combination Therapy: Aliskiren + Valsartan,Male,,Gender,,participants,Number,341,,NA
NCT00927394,B1,Combination Therapy: Aliskiren + Valsartan,TRUE,Combination Therapy: Aliskiren + Valsartan,Female,,Gender,,participants,Number,233,,NA
NCT00927394,B2,Monotherapy: Valsartan,TRUE,Monotherapy: Valsartan,Male,,Gender,,participants,Number,321,,NA
NCT00927394,B2,Monotherapy: Valsartan,TRUE,Monotherapy: Valsartan,Female,,Gender,,participants,Number,244,,NA
NCT00927394,B3,Total,FALSE,,Male,,Gender,,participants,Number,662,,NA
NCT00927394,B3,Total,FALSE,,Female,,Gender,,participants,Number,477,,NA
NCT00931710,B1,Valsartan/Amlodipine/HCTZ,FALSE,,,,Age,,years,Mean,55.0,Standard Deviation,9.83
NCT00931710,B2,Losartan/HCTZ,TRUE,Losartan/HCTZ,,,Age,,years,Mean,57.1,Standard Deviation,9.69
NCT00931710,B3,Total,FALSE,,,,Age,,years,Mean,56.1,Standard Deviation,9.81
NCT00931710,B1,Valsartan/Amlodipine/HCTZ,FALSE,,Male,,Gender,,participants,Number,139,,NA
NCT00931710,B1,Valsartan/Amlodipine/HCTZ,FALSE,,Female,,Gender,,participants,Number,102,,NA
NCT00931710,B2,Losartan/HCTZ,TRUE,Losartan/HCTZ,Male,,Gender,,participants,Number,136,,NA
NCT00931710,B2,Losartan/HCTZ,TRUE,Losartan/HCTZ,Female,,Gender,,participants,Number,111,,NA
NCT00931710,B3,Total,FALSE,,Male,,Gender,,participants,Number,275,,NA
NCT00931710,B3,Total,FALSE,,Female,,Gender,,participants,Number,213,,NA
NCT00942994,B1,Aliskiren / Amlodipine / HCTZ,FALSE,,,,Age,Baseline characteristics are given for Safety Set. The Safety Set included all patients who received at least one dose of double-blind trial medication. One patient was excluded from the Safety Set because the patient was withdrawn from the study without receiving any dose of study medication.,years,Mean,55.7,Standard Deviation,9.79
NCT00942994,B2,Aliskiren / Amlodipine,FALSE,,,,Age,Baseline characteristics are given for Safety Set. The Safety Set included all patients who received at least one dose of double-blind trial medication. One patient was excluded from the Safety Set because the patient was withdrawn from the study without receiving any dose of study medication.,years,Mean,54.7,Standard Deviation,10.19
NCT00942994,B3,Total,FALSE,,,,Age,Baseline characteristics are given for Safety Set. The Safety Set included all patients who received at least one dose of double-blind trial medication. One patient was excluded from the Safety Set because the patient was withdrawn from the study without receiving any dose of study medication.,years,Mean,55.2,Standard Deviation,10.00
NCT00942994,B1,Aliskiren / Amlodipine / HCTZ,FALSE,,Male,,Gender,Baseline characteristics are given for Safety Set. The Safety Set included all patients who received at least one dose of double-blind trial medication. One patient was excluded from the Safety Set because the patient was withdrawn from the study without receiving any dose of study medication.,participants,Number,95,,NA
NCT00942994,B1,Aliskiren / Amlodipine / HCTZ,FALSE,,Female,,Gender,Baseline characteristics are given for Safety Set. The Safety Set included all patients who received at least one dose of double-blind trial medication. One patient was excluded from the Safety Set because the patient was withdrawn from the study without receiving any dose of study medication.,participants,Number,107,,NA
NCT00942994,B2,Aliskiren / Amlodipine,FALSE,,Male,,Gender,Baseline characteristics are given for Safety Set. The Safety Set included all patients who received at least one dose of double-blind trial medication. One patient was excluded from the Safety Set because the patient was withdrawn from the study without receiving any dose of study medication.,participants,Number,109,,NA
NCT00942994,B2,Aliskiren / Amlodipine,FALSE,,Female,,Gender,Baseline characteristics are given for Safety Set. The Safety Set included all patients who received at least one dose of double-blind trial medication. One patient was excluded from the Safety Set because the patient was withdrawn from the study without receiving any dose of study medication.,participants,Number,100,,NA
NCT00942994,B3,Total,FALSE,,Male,,Gender,Baseline characteristics are given for Safety Set. The Safety Set included all patients who received at least one dose of double-blind trial medication. One patient was excluded from the Safety Set because the patient was withdrawn from the study without receiving any dose of study medication.,participants,Number,204,,NA
NCT00942994,B3,Total,FALSE,,Female,,Gender,Baseline characteristics are given for Safety Set. The Safety Set included all patients who received at least one dose of double-blind trial medication. One patient was excluded from the Safety Set because the patient was withdrawn from the study without receiving any dose of study medication.,participants,Number,207,,NA
NCT00949884,B1,Olmesartan,TRUE,Olmesartan,,,Age,,years,Mean,52.0,Standard Deviation,9.84
NCT00949884,B1,Olmesartan,TRUE,Olmesartan,>=65 years,,Age,,participants,Number,35,,NA
NCT00949884,B1,Olmesartan,TRUE,Olmesartan,Between 18 and 65 years,,Age,,participants,Number,385,,NA
NCT00949884,B1,Olmesartan,TRUE,Olmesartan,<=18 years,,Age,,participants,Number,0,,NA
NCT00949884,B2,Placebo Followed by Olmesartan,FALSE,,,,Age,,years,Mean,49.9,Standard Deviation,8.67
NCT00949884,B2,Placebo Followed by Olmesartan,FALSE,,>=65 years,,Age,,participants,Number,1,,NA
NCT00949884,B2,Placebo Followed by Olmesartan,FALSE,,Between 18 and 65 years,,Age,,participants,Number,51,,NA
NCT00949884,B2,Placebo Followed by Olmesartan,FALSE,,<=18 years,,Age,,participants,Number,0,,NA
NCT00949884,B3,Losartan,TRUE,Losartan,,,Age,,years,Mean,52.1,Standard Deviation,9.76
NCT00949884,B3,Losartan,TRUE,Losartan,>=65 years,,Age,,participants,Number,46,,NA
NCT00949884,B3,Losartan,TRUE,Losartan,Between 18 and 65 years,,Age,,participants,Number,423,,NA
NCT00949884,B3,Losartan,TRUE,Losartan,<=18 years,,Age,,participants,Number,0,,NA
NCT00949884,B4,Total,FALSE,,,,Age,,years,Mean,51.9,Standard Deviation,9.74
NCT00949884,B4,Total,FALSE,,>=65 years,,Age,,participants,Number,82,,NA
NCT00949884,B4,Total,FALSE,,Between 18 and 65 years,,Age,,participants,Number,859,,NA
NCT00949884,B4,Total,FALSE,,<=18 years,,Age,,participants,Number,0,,NA
NCT00949884,B1,Olmesartan,TRUE,Olmesartan,,,Body Mass Index,,kilogram/meter^2,Mean,32.41,Standard Deviation,6.089
NCT00949884,B2,Placebo Followed by Olmesartan,FALSE,,,,Body Mass Index,,kilogram/meter^2,Mean,33.62,Standard Deviation,8.103
NCT00949884,B3,Losartan,TRUE,Losartan,,,Body Mass Index,,kilogram/meter^2,Mean,32.28,Standard Deviation,6.619
NCT00949884,B4,Total,FALSE,,,,Body Mass Index,,kilogram/meter^2,Mean,32.41,Standard Deviation,6.480
NCT00949884,B1,Olmesartan,TRUE,Olmesartan,Male,,Gender,,participants,Number,230,,NA
NCT00949884,B1,Olmesartan,TRUE,Olmesartan,Female,,Gender,,participants,Number,190,,NA
NCT00949884,B2,Placebo Followed by Olmesartan,FALSE,,Male,,Gender,,participants,Number,25,,NA
NCT00949884,B2,Placebo Followed by Olmesartan,FALSE,,Female,,Gender,,participants,Number,27,,NA
NCT00949884,B3,Losartan,TRUE,Losartan,Male,,Gender,,participants,Number,258,,NA
NCT00949884,B3,Losartan,TRUE,Losartan,Female,,Gender,,participants,Number,211,,NA
NCT00949884,B4,Total,FALSE,,Male,,Gender,,participants,Number,513,,NA
NCT00949884,B4,Total,FALSE,,Female,,Gender,,participants,Number,428,,NA
NCT00996281,B1,Azilsartan Medoxomil and Chlorthalidone,TRUE,Azilsartan Medoxomil and Chlorthalidone,,,Age,,years,Mean,58.5,Standard Deviation,10.79
NCT00996281,B2,Olmesartan Medoxomil and Hydrochlorothiazide,FALSE,,,,Age,,years,Mean,57.6,Standard Deviation,10.80
NCT00996281,B3,Total,FALSE,,,,Age,,years,Mean,58.1,Standard Deviation,10.80
NCT00996281,B1,Azilsartan Medoxomil and Chlorthalidone,TRUE,Azilsartan Medoxomil and Chlorthalidone,â‰¥75 years,,"Age, Customized",,participants,Number,27,,NA
NCT00996281,B1,Azilsartan Medoxomil and Chlorthalidone,TRUE,Azilsartan Medoxomil and Chlorthalidone,65 to 74 years,,"Age, Customized",,participants,Number,94,,NA
NCT00996281,B1,Azilsartan Medoxomil and Chlorthalidone,TRUE,Azilsartan Medoxomil and Chlorthalidone,45 to 64 years,,"Age, Customized",,participants,Number,251,,NA
NCT00996281,B1,Azilsartan Medoxomil and Chlorthalidone,TRUE,Azilsartan Medoxomil and Chlorthalidone,<45 years,,"Age, Customized",,participants,Number,46,,NA
NCT00996281,B2,Olmesartan Medoxomil and Hydrochlorothiazide,FALSE,,â‰¥75 years,,"Age, Customized",,participants,Number,19,,NA
NCT00996281,B2,Olmesartan Medoxomil and Hydrochlorothiazide,FALSE,,65 to 74 years,,"Age, Customized",,participants,Number,93,,NA
NCT00996281,B2,Olmesartan Medoxomil and Hydrochlorothiazide,FALSE,,45 to 64 years,,"Age, Customized",,participants,Number,259,,NA
NCT00996281,B2,Olmesartan Medoxomil and Hydrochlorothiazide,FALSE,,<45 years,,"Age, Customized",,participants,Number,48,,NA
NCT00996281,B3,Total,FALSE,,â‰¥75 years,,"Age, Customized",,participants,Number,46,,NA
NCT00996281,B3,Total,FALSE,,65 to 74 years,,"Age, Customized",,participants,Number,187,,NA
NCT00996281,B3,Total,FALSE,,45 to 64 years,,"Age, Customized",,participants,Number,510,,NA
NCT00996281,B3,Total,FALSE,,<45 years,,"Age, Customized",,participants,Number,94,,NA
NCT00996281,B1,Azilsartan Medoxomil and Chlorthalidone,TRUE,Azilsartan Medoxomil and Chlorthalidone,,,Body Mass Index (BMI),,kg/m^2,Mean,31.4,Standard Deviation,6.21
NCT00996281,B2,Olmesartan Medoxomil and Hydrochlorothiazide,FALSE,,,,Body Mass Index (BMI),,kg/m^2,Mean,31.9,Standard Deviation,6.63
NCT00996281,B3,Total,FALSE,,,,Body Mass Index (BMI),,kg/m^2,Mean,31.7,Standard Deviation,6.42
NCT00996281,B1,Azilsartan Medoxomil and Chlorthalidone,TRUE,Azilsartan Medoxomil and Chlorthalidone,Male,,Gender,,participants,Number,226,,NA
NCT00996281,B1,Azilsartan Medoxomil and Chlorthalidone,TRUE,Azilsartan Medoxomil and Chlorthalidone,Female,,Gender,,participants,Number,192,,NA
NCT00996281,B2,Olmesartan Medoxomil and Hydrochlorothiazide,FALSE,,Male,,Gender,,participants,Number,246,,NA
NCT00996281,B2,Olmesartan Medoxomil and Hydrochlorothiazide,FALSE,,Female,,Gender,,participants,Number,173,,NA
NCT00996281,B3,Total,FALSE,,Male,,Gender,,participants,Number,472,,NA
NCT00996281,B3,Total,FALSE,,Female,,Gender,,participants,Number,365,,NA
NCT01001572,B1,Valsartan/Amlodipine 160/5 mg,FALSE,,,,Age,Baseline Measures were based on the Full Analysis Set that excludes 3 participants for having no post-baseline efficacy assessment.,years,Mean,52.9,Standard Deviation,9.47
NCT01001572,B2,Valsartan 160 mg,TRUE,Valsartan 160 mg,,,Age,Baseline Measures were based on the Full Analysis Set that excludes 3 participants for having no post-baseline efficacy assessment.,years,Mean,53.1,Standard Deviation,9.41
NCT01001572,B3,Total,FALSE,,,,Age,Baseline Measures were based on the Full Analysis Set that excludes 3 participants for having no post-baseline efficacy assessment.,years,Mean,53.0,Standard Deviation,9.43
NCT01001572,B1,Valsartan/Amlodipine 160/5 mg,FALSE,,Male,,Gender,,participants,Number,187,,NA
NCT01001572,B1,Valsartan/Amlodipine 160/5 mg,FALSE,,Female,,Gender,,participants,Number,141,,NA
NCT01001572,B2,Valsartan 160 mg,TRUE,Valsartan 160 mg,Male,,Gender,,participants,Number,173,,NA
NCT01001572,B2,Valsartan 160 mg,TRUE,Valsartan 160 mg,Female,,Gender,,participants,Number,150,,NA
NCT01001572,B3,Total,FALSE,,Male,,Gender,,participants,Number,360,,NA
NCT01001572,B3,Total,FALSE,,Female,,Gender,,participants,Number,291,,NA
NCT01033071,B1,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,,,Age,,years,Mean,56.4,Standard Deviation,10.49
NCT01033071,B2,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,,,Age,,years,Mean,56.7,Standard Deviation,10.07
NCT01033071,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,TRUE,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,,,Age,,years,Mean,56.7,Standard Deviation,10.86
NCT01033071,B4,Total,FALSE,,,,Age,,years,Mean,56.6,Standard Deviation,10.47
NCT01033071,B1,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,â‰¥65 years,,"Age, Customized",,participants,Number,74,,NA
NCT01033071,B1,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,Between 45 to 64 years,,"Age, Customized",,participants,Number,235,,NA
NCT01033071,B1,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,<45 years,,"Age, Customized",,participants,Number,46,,NA
NCT01033071,B2,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,â‰¥65 years,,"Age, Customized",,participants,Number,78,,NA
NCT01033071,B2,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,Between 45 to 64 years,,"Age, Customized",,participants,Number,241,,NA
NCT01033071,B2,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,<45 years,,"Age, Customized",,participants,Number,33,,NA
NCT01033071,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,TRUE,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,â‰¥65 years,,"Age, Customized",,participants,Number,84,,NA
NCT01033071,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,TRUE,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,Between 45 to 64 years,,"Age, Customized",,participants,Number,234,,NA
NCT01033071,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,TRUE,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,<45 years,,"Age, Customized",,participants,Number,46,,NA
NCT01033071,B4,Total,FALSE,,â‰¥65 years,,"Age, Customized",,participants,Number,236,,NA
NCT01033071,B4,Total,FALSE,,Between 45 to 64 years,,"Age, Customized",,participants,Number,710,,NA
NCT01033071,B4,Total,FALSE,,<45 years,,"Age, Customized",,participants,Number,125,,NA
NCT01033071,B1,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,,,Body Mass Index (BMI),,kg/m2,Mean,31.4,Standard Deviation,5.94
NCT01033071,B2,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,,,Body Mass Index (BMI),,kg/m2,Mean,31.9,Standard Deviation,6.59
NCT01033071,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,TRUE,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,,,Body Mass Index (BMI),,kg/m2,Mean,31.6,Standard Deviation,5.92
NCT01033071,B4,Total,FALSE,,,,Body Mass Index (BMI),,kg/m2,Mean,31.6,Standard Deviation,6.15
NCT01033071,B1,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,Male,,Gender,,participants,Number,223,,NA
NCT01033071,B1,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 20-40mg/Chlorthalidone 12.5-25mg QD,Female,,Gender,,participants,Number,132,,NA
NCT01033071,B2,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,Male,,Gender,,participants,Number,201,,NA
NCT01033071,B2,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,TRUE,Azilsartan Medoxomil 40-80mg/Chlorthalidone 12.5-25mg QD,Female,,Gender,,participants,Number,151,,NA
NCT01033071,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,TRUE,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,Male,,Gender,,participants,Number,205,,NA
NCT01033071,B3,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,TRUE,Olmesartan Medoxomil 20-40mg/Hydrochlorothiazide 12.5-25mg QD,Female,,Gender,,participants,Number,159,,NA
NCT01033071,B4,Total,FALSE,,Male,,Gender,,participants,Number,629,,NA
NCT01033071,B4,Total,FALSE,,Female,,Gender,,participants,Number,442,,NA
NCT01042392,B1,Ramipril,TRUE,Ramipril,,,Age,,years,Mean,59.8,Standard Deviation,11.6
NCT01042392,B2,Aliskiren,TRUE,Aliskiren,,,Age,,years,Mean,61.0,Standard Deviation,11.4
NCT01042392,B3,Total,FALSE,,,,Age,,years,Mean,60.4,Standard Deviation,11.5
NCT01042392,B1,Ramipril,TRUE,Ramipril,>= 75 years,,"Age, Customized",,Participants,Number,26,,NA
NCT01042392,B1,Ramipril,TRUE,Ramipril,65 - 74 years,,"Age, Customized",,Participants,Number,56,,NA
NCT01042392,B1,Ramipril,TRUE,Ramipril,50 - 64 years,,"Age, Customized",,Participants,Number,119,,NA
NCT01042392,B1,Ramipril,TRUE,Ramipril,< 50 years,,"Age, Customized",,Participants,Number,56,,NA
NCT01042392,B2,Aliskiren,TRUE,Aliskiren,>= 75 years,,"Age, Customized",,Participants,Number,31,,NA
NCT01042392,B2,Aliskiren,TRUE,Aliskiren,65 - 74 years,,"Age, Customized",,Participants,Number,64,,NA
NCT01042392,B2,Aliskiren,TRUE,Aliskiren,50 - 64 years,,"Age, Customized",,Participants,Number,115,,NA
NCT01042392,B2,Aliskiren,TRUE,Aliskiren,< 50 years,,"Age, Customized",,Participants,Number,39,,NA
NCT01042392,B3,Total,FALSE,,>= 75 years,,"Age, Customized",,Participants,Number,57,,NA
NCT01042392,B3,Total,FALSE,,65 - 74 years,,"Age, Customized",,Participants,Number,120,,NA
NCT01042392,B3,Total,FALSE,,50 - 64 years,,"Age, Customized",,Participants,Number,234,,NA
NCT01042392,B3,Total,FALSE,,< 50 years,,"Age, Customized",,Participants,Number,95,,NA
NCT01042392,B1,Ramipril,TRUE,Ramipril,Male,,Gender,,participants,Number,115,,NA
NCT01042392,B1,Ramipril,TRUE,Ramipril,Female,,Gender,,participants,Number,142,,NA
NCT01042392,B2,Aliskiren,TRUE,Aliskiren,Male,,Gender,,participants,Number,116,,NA
NCT01042392,B2,Aliskiren,TRUE,Aliskiren,Female,,Gender,,participants,Number,133,,NA
NCT01042392,B3,Total,FALSE,,Male,,Gender,,participants,Number,231,,NA
NCT01042392,B3,Total,FALSE,,Female,,Gender,,participants,Number,275,,NA
NCT01167153,B1,Valsartan/Amlodipine,FALSE,,,,Age,"demographic measures were based on intent to treat (ITT) population. One patient was missing from Nifedipine arm for Age, continuous measurement.",years,Mean,53.8,Standard Deviation,8.59
NCT01167153,B2,Nifedipine,TRUE,Nifedipine,,,Age,"demographic measures were based on intent to treat (ITT) population. One patient was missing from Nifedipine arm for Age, continuous measurement.",years,Mean,53.1,Standard Deviation,8.72
NCT01167153,B3,Total,FALSE,,,,Age,"demographic measures were based on intent to treat (ITT) population. One patient was missing from Nifedipine arm for Age, continuous measurement.",years,Mean,53.5,Standard Deviation,8.63
NCT01167153,B1,Valsartan/Amlodipine,FALSE,,Male,,Gender,,participants,Number,137,,NA
NCT01167153,B1,Valsartan/Amlodipine,FALSE,,Female,,Gender,,participants,Number,135,,NA
NCT01167153,B2,Nifedipine,TRUE,Nifedipine,Male,,Gender,,participants,Number,133,,NA
NCT01167153,B2,Nifedipine,TRUE,Nifedipine,Female,,Gender,,participants,Number,135,,NA
NCT01167153,B3,Total,FALSE,,Male,,Gender,,participants,Number,270,,NA
NCT01167153,B3,Total,FALSE,,Female,,Gender,,participants,Number,270,,NA
NCT01237223,B1,Placebo,TRUE,Placebo,,,Age,Baseline measurements were based on randomized patients.,years,Mean,54.6,Standard Deviation,8.35
NCT01237223,B2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,,,Age,Baseline measurements were based on randomized patients.,years,Mean,55.0,Standard Deviation,9.96
NCT01237223,B3,Amlodipine 2.5 mg,TRUE,Amlodipine 2.5 mg,,,Age,Baseline measurements were based on randomized patients.,years,Mean,54.8,Standard Deviation,10.25
NCT01237223,B4,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,,,Age,Baseline measurements were based on randomized patients.,years,Mean,55.8,Standard Deviation,10.05
NCT01237223,B5,Aliskiren/Amlodipine 150/2.5 mg,FALSE,,,,Age,Baseline measurements were based on randomized patients.,years,Mean,54.6,Standard Deviation,11.11
NCT01237223,B6,Aliskiren/Amlodipine 150/5 mg,FALSE,,,,Age,Baseline measurements were based on randomized patients.,years,Mean,55.5,Standard Deviation,9.86
NCT01237223,B7,Total,FALSE,,,,Age,Baseline measurements were based on randomized patients.,years,Mean,55.1,Standard Deviation,9.96
NCT01237223,B1,Placebo,TRUE,Placebo,>=65 years,,"Age, Customized",,participants,Number,25,,NA
NCT01237223,B1,Placebo,TRUE,Placebo,< 65 years,,"Age, Customized",,participants,Number,128,,NA
NCT01237223,B2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,>=65 years,,"Age, Customized",,participants,Number,26,,NA
NCT01237223,B2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,< 65 years,,"Age, Customized",,participants,Number,131,,NA
NCT01237223,B3,Amlodipine 2.5 mg,TRUE,Amlodipine 2.5 mg,>=65 years,,"Age, Customized",,participants,Number,29,,NA
NCT01237223,B3,Amlodipine 2.5 mg,TRUE,Amlodipine 2.5 mg,< 65 years,,"Age, Customized",,participants,Number,129,,NA
NCT01237223,B4,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,>=65 years,,"Age, Customized",,participants,Number,32,,NA
NCT01237223,B4,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,< 65 years,,"Age, Customized",,participants,Number,126,,NA
NCT01237223,B5,Aliskiren/Amlodipine 150/2.5 mg,FALSE,,>=65 years,,"Age, Customized",,participants,Number,34,,NA
NCT01237223,B5,Aliskiren/Amlodipine 150/2.5 mg,FALSE,,< 65 years,,"Age, Customized",,participants,Number,125,,NA
NCT01237223,B6,Aliskiren/Amlodipine 150/5 mg,FALSE,,>=65 years,,"Age, Customized",,participants,Number,32,,NA
NCT01237223,B6,Aliskiren/Amlodipine 150/5 mg,FALSE,,< 65 years,,"Age, Customized",,participants,Number,127,,NA
NCT01237223,B7,Total,FALSE,,>=65 years,,"Age, Customized",,participants,Number,178,,NA
NCT01237223,B7,Total,FALSE,,< 65 years,,"Age, Customized",,participants,Number,766,,NA
NCT01237223,B1,Placebo,TRUE,Placebo,Male,,Gender,,participants,Number,108,,NA
NCT01237223,B1,Placebo,TRUE,Placebo,Female,,Gender,,participants,Number,45,,NA
NCT01237223,B2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,Male,,Gender,,participants,Number,118,,NA
NCT01237223,B2,Aliskiren 150 mg,TRUE,Aliskiren 150 mg,Female,,Gender,,participants,Number,39,,NA
NCT01237223,B3,Amlodipine 2.5 mg,TRUE,Amlodipine 2.5 mg,Male,,Gender,,participants,Number,113,,NA
NCT01237223,B3,Amlodipine 2.5 mg,TRUE,Amlodipine 2.5 mg,Female,,Gender,,participants,Number,45,,NA
NCT01237223,B4,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,Male,,Gender,,participants,Number,107,,NA
NCT01237223,B4,Amlodipine 5 mg,TRUE,Amlodipine 5 mg,Female,,Gender,,participants,Number,51,,NA
NCT01237223,B5,Aliskiren/Amlodipine 150/2.5 mg,FALSE,,Male,,Gender,,participants,Number,108,,NA
NCT01237223,B5,Aliskiren/Amlodipine 150/2.5 mg,FALSE,,Female,,Gender,,participants,Number,51,,NA
NCT01237223,B6,Aliskiren/Amlodipine 150/5 mg,FALSE,,Male,,Gender,,participants,Number,102,,NA
NCT01237223,B6,Aliskiren/Amlodipine 150/5 mg,FALSE,,Female,,Gender,,participants,Number,57,,NA
NCT01237223,B7,Total,FALSE,,Male,,Gender,,participants,Number,656,,NA
NCT01237223,B7,Total,FALSE,,Female,,Gender,,participants,Number,288,,NA
NCT01368536,B1,Valturna,TRUE,Valturna,,,Age,,Years,Mean,54.7,Standard Deviation,8.65
NCT01368536,B2,Valturna + Amlodipine,TRUE,Valturna + Amlodipine,,,Age,,Years,Mean,56.0,Standard Deviation,9.56
NCT01368536,B3,Valturna + Chlorthalidone,FALSE,,,,Age,,Years,Mean,54.6,Standard Deviation,9.35
NCT01368536,B4,Total,FALSE,,,,Age,,Years,Mean,55.1,Standard Deviation,9.20
NCT01368536,B1,Valturna,TRUE,Valturna,Male,,Gender,,Participants,Number,65,,NA
NCT01368536,B1,Valturna,TRUE,Valturna,Female,,Gender,,Participants,Number,73,,NA
NCT01368536,B2,Valturna + Amlodipine,TRUE,Valturna + Amlodipine,Male,,Gender,,Participants,Number,64,,NA
NCT01368536,B2,Valturna + Amlodipine,TRUE,Valturna + Amlodipine,Female,,Gender,,Participants,Number,73,,NA
NCT01368536,B3,Valturna + Chlorthalidone,FALSE,,Male,,Gender,,Participants,Number,71,,NA
NCT01368536,B3,Valturna + Chlorthalidone,FALSE,,Female,,Gender,,Participants,Number,70,,NA
NCT01368536,B4,Total,FALSE,,Male,,Gender,,Participants,Number,200,,NA
NCT01368536,B4,Total,FALSE,,Female,,Gender,,Participants,Number,216,,NA
NCT01599104,B1,LCZ696 200 mg,TRUE,LCZ696 200 mg,,,Age,,Years,Mean,57.9,Standard Deviation,10.87
NCT01599104,B2,LCZ696 400 mg,TRUE,LCZ696 400 mg,,,Age,,Years,Mean,58.7,Standard Deviation,10.50
NCT01599104,B3,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,,,Age,,Years,Mean,59.6,Standard Deviation,10.50
NCT01599104,B4,Total,FALSE,,,,Age,,Years,Mean,58.7,Standard Deviation,10.64
NCT01599104,B1,LCZ696 200 mg,TRUE,LCZ696 200 mg,Male,,Gender,,Participants,Number,264,,NA
NCT01599104,B1,LCZ696 200 mg,TRUE,LCZ696 200 mg,Female,,Gender,,Participants,Number,123,,NA
NCT01599104,B2,LCZ696 400 mg,TRUE,LCZ696 400 mg,Male,,Gender,,Participants,Number,268,,NA
NCT01599104,B2,LCZ696 400 mg,TRUE,LCZ696 400 mg,Female,,Gender,,Participants,Number,117,,NA
NCT01599104,B3,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,Male,,Gender,,Participants,Number,286,,NA
NCT01599104,B3,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,Female,,Gender,,Participants,Number,103,,NA
NCT01599104,B4,Total,FALSE,,Male,,Gender,,Participants,Number,818,,NA
NCT01599104,B4,Total,FALSE,,Female,,Gender,,Participants,Number,343,,NA
NCT01615198,B1,LCZ696,TRUE,LCZ696,,,Age,,Years,Mean,70.5,Standard Deviation,4.67
NCT01615198,B2,Olmesartan,TRUE,Olmesartan,,,Age,,Years,Mean,70.9,Standard Deviation,4.67
NCT01615198,B3,Total,FALSE,,,,Age,,Years,Mean,70.7,Standard Deviation,4.67
NCT01615198,B1,LCZ696,TRUE,LCZ696,Male,,Gender,,Participants,Number,142,,NA
NCT01615198,B1,LCZ696,TRUE,LCZ696,Female,,Gender,,Participants,Number,154,,NA
NCT01615198,B2,Olmesartan,TRUE,Olmesartan,Male,,Gender,,Participants,Number,152,,NA
NCT01615198,B2,Olmesartan,TRUE,Olmesartan,Female,,Gender,,Participants,Number,140,,NA
NCT01615198,B3,Total,FALSE,,Male,,Gender,,Participants,Number,294,,NA
NCT01615198,B3,Total,FALSE,,Female,,Gender,,Participants,Number,294,,NA
NCT01785472,B1,LCZ696 200 mg,TRUE,LCZ696 200 mg,,,Age,,Years,Mean,57.5,Standard Deviation,10.17
NCT01785472,B2,LCZ696 400 mg,TRUE,LCZ696 400 mg,,,Age,,Years,Mean,58.1,Standard Deviation,9.71
NCT01785472,B3,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,,,Age,,Years,Mean,57.4,Standard Deviation,10.14
NCT01785472,B4,Total,FALSE,,,,Age,,Years,Mean,57.7,Standard Deviation,10.01
NCT01785472,B1,LCZ696 200 mg,TRUE,LCZ696 200 mg,,Male,Gender,,Participants,Count of Participants,252,,NA
NCT01785472,B1,LCZ696 200 mg,TRUE,LCZ696 200 mg,,Female,Gender,,Participants,Count of Participants,227,,NA
NCT01785472,B2,LCZ696 400 mg,TRUE,LCZ696 400 mg,,Male,Gender,,Participants,Count of Participants,243,,NA
NCT01785472,B2,LCZ696 400 mg,TRUE,LCZ696 400 mg,,Female,Gender,,Participants,Count of Participants,229,,NA
NCT01785472,B3,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,,Male,Gender,,Participants,Count of Participants,261,,NA
NCT01785472,B3,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,,Female,Gender,,Participants,Count of Participants,223,,NA
NCT01785472,B4,Total,FALSE,,,Male,Gender,,Participants,Count of Participants,756,,NA
NCT01785472,B4,Total,FALSE,,,Female,Gender,,Participants,Count of Participants,679,,NA
NCT01876368,B1,LCZ696 200 mg,TRUE,LCZ696 200 mg,,,Age,,Years,Mean,57.1,Standard Deviation,10.19
NCT01876368,B2,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,,,Age,,Years,Mean,58.0,Standard Deviation,9.09
NCT01876368,B3,Total,FALSE,,,,Age,,Years,Mean,57.6,Standard Deviation,9.65
NCT01876368,B1,LCZ696 200 mg,TRUE,LCZ696 200 mg,Male,,Gender,,Participants,Number,97,,NA
NCT01876368,B1,LCZ696 200 mg,TRUE,LCZ696 200 mg,Female,,Gender,,Participants,Number,91,,NA
NCT01876368,B2,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,Male,,Gender,,Participants,Number,95,,NA
NCT01876368,B2,Olmesartan 20 mg,TRUE,Olmesartan 20 mg,Female,,Gender,,Participants,Number,92,,NA
NCT01876368,B3,Total,FALSE,,Male,,Gender,,Participants,Number,192,,NA
NCT01876368,B3,Total,FALSE,,Female,,Gender,,Participants,Number,183,,NA
NCT01975246,B1,Telmisartan and Amlodipine+HCTZ,FALSE,,,,Age,,Years,Mean,54.4,Standard Deviation,9.1
NCT01975246,B2,Telmisartan+Amlodipine,FALSE,,,,Age,,Years,Mean,55.0,Standard Deviation,9.7
NCT01975246,B3,Total,FALSE,,,,Age,,Years,Mean,54.7,Standard Deviation,9.4
NCT01975246,B1,Telmisartan and Amlodipine+HCTZ,FALSE,,Male,,Gender,,Participants,Number,127,,NA
NCT01975246,B1,Telmisartan and Amlodipine+HCTZ,FALSE,,Female,,Gender,,Participants,Number,22,,NA
NCT01975246,B2,Telmisartan+Amlodipine,FALSE,,Male,,Gender,,Participants,Number,130,,NA
NCT01975246,B2,Telmisartan+Amlodipine,FALSE,,Female,,Gender,,Participants,Number,30,,NA
NCT01975246,B3,Total,FALSE,,Male,,Gender,,Participants,Number,257,,NA
NCT01975246,B3,Total,FALSE,,Female,,Gender,,Participants,Number,52,,NA
